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  9I Introduction 
1 Historical  Overview 
After the discovery of 3’,5’-cyclic adenosine monophosphate (cAMP)  as the first 
second messenger molecule that regulates many important cell functions 
(Sutherland EW, 1958) guanosine 3',5'-monophosphate (cGMP) became the 
second identified member of this important class of signaling molecules, the 
cyclic nucleotides (Ashman DF, 1963). cGMP is involved in the regulation of 
vision, vasodilatation, platelet aggregation, smooth muscle cell proliferation, 
cellular ion homeostasis, synaptic plasticity and other important physiological 
processes (Carvajal JA, 2000);(McDonald LJ, 1995);(Sausbier M, 2000).  
Cyclic GMP is synthesised by the guanylyl cyclase family of enzymes. It was 
established by the mid-1970s that guanylyl cyclase activity is present in both the 
soluble and particulate fractions
  of most cells (Schultz G, 1969);(White AA, 
1969);(Hardman JG, 1969);(Ishikawa E, 1969), and that
 these activities are due 
to different proteins (Garbers DL, 1974);(Kimura H, 1974);(Kimura H, 1975a). 
Therefore, guanylyl cyclases are divided into two subfamilies: particulate and 
soluble guanylyl cyclases (sGC) (Chrisman TD, 1975);(Garbers DL., 1990). 
 
1.1  Role of Nitric Oxide (NO) 
While a number of peptide hormones that stimulate particulate guanylyl cyclase 
were known for some time (Waldman SA, 1985);(Murad F, 1987), the nature of 
the physiological regulator of sGC remained for long time enigmatic. Already in 
the 1970s, NO-releasing compounds were found to be
 potent activators of NO-
sensitive GC (Arnold WP, 1977);(Bohme E, 1978). Similarly, nitrovasodilators
 like 
glyceroltrinitrate or isosorbid dinitrate therapeutically
  used for the treatment of 
coronary heart disease act by stimulation
 of the enzyme. These nitrates do not 
  10release NO spontaneously;
 instead, they have to undergo bioactivation that either 
yields
 NO or nitrosothiols.
 
Despite the stimulatory effect of these NO-containing compounds,
  the 
physiological significance of NO-induced activation of the
  enzyme did not 
become apparent until the identification of endothelium-derived
  relaxing factor 
(EDRF) as NO (Ignarro LJ, 1987);(Palmer RM, 1987).
 Formation of EDRF had 
been
  shown to occur in endothelial cells in response to vasodilatory
  agonists 
such as acetylcholine, histamine, or bradykinin, leading
 to vasodilation via the 
activation of NO-sensitive GC in smooth
 muscle cells (Forstermann U, 1986).
 
After the discovery of NO in the vascular system,
 NO formation was reported to 
occur throughout the body (Moncada S, 1995). The
 enzymes responsible for the 
synthesis of NO were identified
  and termed NO synthases of which three 
isoforms are known to
  date (neuronal NOS-NOS I, inducible NOS-NOS II, 
endothelial NOS-NOS III). These enzymes catalyze the oxidative deamination of 
the amino acid L-arginine, wherein by the consumption of 1.5 mol of NADPH and 
2 mol of oxygen, a mol of NO is formed (Griffith OW, 1995). From two sequential 
monooxygenase reactions the final products NO and L-citrulline are synthesized 
(Marletta MA, 1988). The endothelial NO synthase is a
 constitutively expressed 
enzyme that shows a low basal activity, which is increased however by hormonal 
induced rise in the cytosolic Ca
2+-concentration which is regulated by calmodulin 
(Busse R, 1990);(Lamas S, 1992). The endothelial NO synthase is also activated
 
by Akt/PKB-dependent phosphorylation triggered by shear forces
 exerted on the 
endothelial cells (Dimmeler S, 1999). 
  11 
Figure 1.  Current scheme for endothelium-dependent relaxation. 
Endothelial cells possess receptors on their cell membrane, for example 
for acetylcholine (M), ATP (P), histamine (H1), endothelin (ETB) and 
thrombin (T). Through G-proteins these factors can induce the activation 
of phospholipase C, which catalyzes the conversion of 
phosphatidylinositol-4, 5-bisphosphate (PIP2) in inositol-1, 4, 5-triphosphat 
e (IP3) and diacylglycerine (DAG). IP3 sets Ca
2+ free from intracellular 
stores.  This leads to the activation of the Ca
2+/calmodulin-dependent 
endothelial NO synthase (NOS III), which forms NO and L-citrulline from 
oxygen and L-arginine. NO diffuses into the smooth muscle cells and 
stimulates the soluble guanylyl cyclase (sGC), which leads to cGMP 
accumulation and activation of the cGMP dependent protein kinases (G-
kinases) which leads to vasorelaxation. 
In-vivo investigations indicate that endothelial NO plays an important role 
in vascular homeostasis in humans and mammals (Furchgott RF, 
1989);(Ignarro LJ, 1987);(Moncada S, 1991);(Rees DD, 1989);(Vallance 
P, 1989). Consequently disturbances of the NO /cGMP system lead to 
  12diseases with vascular dysfunction.  Another important mechanism is the 
reaction of NO with the superoxide radical leading to the formation of 
peroxynitrite (Beckmann JS, 1994) which in turn can lead to the nitration 
of other compounds such as prostacycline synthase (Zou MH, 1996). NO-
mediated signaling has been implicated in
  vasodilatation, inhibition of 
leukocyte adhesion and platelet
  aggregation, regulation of endothelial 
permeability, neuronal
  signaling in the peripheral and central nervous 
system, and
 other processes (Zhuo M, 1995);(Walter U., 1989);(Rapoport 
RM, 1983);(Moncada S, 1995). 
 
1.2  Role of cGMP 
 
 
Figure 2. Cyclic GMP signaling pathway. Cyclic GMP is synthesized by 
soluble guanylate cyclases in response to NO or by receptor guanylate cyclases, 
which are activated by natriuretic peptides, for example. Depending on the cell 
type, cGMP has several intracellular targets in addition to cGMP-dependent 
protein kinases (PKG). 
 
  13cGMP mediates its effects through four cellular proteins: cGMP dependent 
protein kinases (PKG), cyclic nucleotide-gated cation channels (CNG), cAMP 
dependent protein kinases (PKA) and phosphodiesterases (PDE) (Lucas KA, 
2000).  
 
The PKGs are serine/threonine kinases, which are activated by cGMP. Two 
types of PKG are well known:  PKG I and PKG II. The PKG I is a cytosolic 76-
kDa homodimer. It is expressed in most tissues and more strongly particularly in 
the cerebellum, in the blood cells and in the smooth muscle cells.  Two isoforms 
of the PKG I were described, PKG PKG Iα and PKG Iβ.  Most tissue with the 
exception of uterus, express both isoforms (Lohmann SM, 1997);( Tamura N, 
1996). In mice, in which the gene for PKGI was switched off, vascular, intestinal, 
and erectile dysfunctions were described (Hedlund P, 2000);(Pfeifer A, 1998). 
 
The PKG II is a 86 kDa protein, which is also expressed in a large number of 
tissues though not in the cardiovascular system (Jarchau T, 1994);( Lohmann 
SM, 1997);( Uhler MD., 1993). The only well-known target substrate of the PKG II 
is the cystic fibrosis transmembrane conductance regulator (CFTR) (Vaandrager 
AB, 1997). In knockout studies in mice intestinal secretion defects and dwarf 
stature were observed. 
 
CNG channels are a family of voltage-gated cation channels expressed in a 
variety of cells. There are five isoforms of the CNG (Biel M, 1999);(Frings S., 
1997);(McCoy DE, 1995);(Misaka T, 1997). The isoforms CNG 1 and CNG 3 are 
involved in cGMP-mediated phototransduction at the level of rod and cone 
photoreceptors that regulates neurotransmission within the
 retina.  
 
Although cGMP is not the classical substrate for PKA, it can still activatePKA.  
The regions responsible for binding to the cyclic nucleotides in PKA are very 
similar to PKG. However the selectivity for the activation of PKA by cGMP is less 
by a factor of 50 as compared to  PKG (Lohmann SM, 1997);(Pfeifer A, 1998). 
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The phosphodiesterase (PDE) is the last group of the cGMP activated signal 
molecules. These enzymes catalyze the conversion from cAMP or cGMP to 5'-
AMP or 5'-GMP, which do not possess any biological activity.  Altogether 13 PDE 
isoenzymes have been described to date, of which the first five are:  the 
calcium/calmodulin dependent PDE I, the cGMP stimulated PDE II, the one 
inhibited by cGMP (PDE III), cAMP specific PDE IV and the cGMP specific PDE 
V (Pfeifer A, 1998);(Schmidt HH, 1993).  Of particular importance is the cGMP 
specific PDE V, which is central for the signal transduction in the retinal rods and 
cones. 
 
 
 
Figure 3. NO/cGMP signaling cascade. NO endogenously produced by NO 
synthases or released from exogenously applied NO donors activates NO-
sensitive sGC and leads to increased synthesis of cGMP. This intracellular 
messenger in turn modulates the activity of cGMP-dependent kinases, cGMP-
gated ion channels, and cGMP-regulated phosphodiesterases. These effectors 
are involved in the regulation of several physiological functions in the 
cardiovascular and nervous systems. YC-1 and BAY 58-2667 represent new 
classes of activators of NO-sensitive GC (Friebe A, 2003). 
 
  152 Guanylyl  Cyclase 
2.1  Particulate Guanylyl Cyclase (pGC) 
Seven eutherian mammalian pGC isoforms (GC-A to GC-G) have been identified 
(Table 1). They exhibit highly conserved domain
  structures, including (1) an 
extracellular binding domain at the
 N terminus that in some cases binds defined 
ligands (GC-A, -B,
 -C), (2) a single transmembrane domain, (3) a cytoplasmic 
juxtamembrane
 domain, (4) a regulatory domain that shares significant homology
 
with protein kinases, (5) a hinge region, and (6) a C-terminal
 catalytic domain 
(Figure 4). Isoforms expressed in intestinal mucosal
 cells (GC-C) and in sensory 
organs (GC-D, -E, -F) also possess
  a C-terminal tail. Based on their ligand 
specificities, pGCs have been classified as (1) natriuretic peptide receptors, (2) 
intestinal peptide-binding
 receptors, and (3) orphan receptors (Table 1). pGCs 
are expressed in almost all tissues in placental mammals (Table 1). 
 
Table 1: Particulate guanylyl cyclase isoforms, ligand and co-factor 
specificities, chromosomal localisation and tissue distribution.  
 
 
Ligand(s) Cofactors Chromosome 
Location 
Tissue Distribution 
GC-A  
(NPR-A) 
ANP,  BNP  ATP  1p21-p22  Adipose tissue, adrenal 
gland, ileum, kidney, 
placenta; adrenal gland, 
cerebellum, heart, kidney, 
pituitary; lamina propria; 
cochlea; thymus ovary 
GC-B  
(NPR-B) 
CNP  ATP  9p12-p21  Placenta; adrenal medulla, 
cerebellum, pituitary; adrenal 
gland, aorta, atrium, 
cerebellum, lung, intestine, 
pituitary, testis, ventricle; 
uterus/oviduct; thymus; 
ovary 
GC-C ST,  Guanylin, 
Uroguanylin 
 12p12  Intestinal  mucosa; 
regenerating liver  
GC-D ?    11p15.4  or 
11q13-q14.1 
Olfactory epithelium 
GC-E  
(Ret GC-1) 
?  GCAP1,2,3  17p13.1  Retina, pineal gland 
GC-F  
(Ret GC-2) 
? GCAP  2,3  Xq22 Retina 
GC-G ?    10q24-q26c  Intestine,  kidney,  lung, 
skeletal muscle 
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Figure 4: Domain structure of particulate guanylyl cyclases (pGC). The 
pGCs are homodimeric proteins that possess extracellular ligand binding domain, 
a transmembrane, kinase homology domain, a hinge region and a GC catalytic 
domain. The pGC illustrated is a homodimer modeled after GC-A and B and 
possess a single ligand binding site formed by two extracellular amino terminal 
domains. GC-C, D, E and F possess a carboxy terminal tail that is not depicted 
here (Lucas et al., 2000). 
 
 
  172.2  Soluble Guanylyl Cyclase (sGC) 
The purification of guanylyl cyclase from the 100,000xg centrifugation 
supernatant of tissue extracts showed that the soluble isoform is a heterodimer, 
consisting of an α and a β subunit exhibiting a molecular weight of ~70 kDa and 
~73 to 82 kDa respectively (Kamisaki Y, 1986). It was another four years, until 
sGC in pure form was isolated from bovine or rat lung, the primary sequence was 
obtained and the catalytic domain was identified (Nakane M, 1988);(Koesling D, 
1988);(Nakane M, 1990).  
 
The soluble guanylyl cyclase (sGC) is found in the cytoplasm of nearly all 
mammalian cells (not in red blood cells) and mediates a large range of important 
physiological processes like the inhibition of platelet aggregation (Buechler WA, 
1994), relaxation of smooth muscle (Warner TD, 1994), vasodilation, neuronal 
signal transduction and immune modulation (Collier J, 1999). 
2.2.1  Isotypes of sGC 
Table 2: Soluble guanylyl cyclase isoform chromosome localisation and 
tissue distribution  
 
Subunit 
 
Chromosome 
Location 
 
Tissue Distribution 
α1 (α3)  4q31.3-q33 Lung;  cerebellum, cerebrum, heart, 
kidney, liver, lung skeletal muscle; 
kidney 
α2  11q21-q22  Brain, retina; kidney; placenta 
β1 (β3)  4q31.3-q33 Lung;  cerebellum, cerebrum, heart, 
kidney, liver, lung skeletal muscle  
β2  13q14.3  Kidney, liver; kidney 
 
Presently, five different subunits of sGC are well known to exist: α-1, α-2, α-i, β-1 
and  β-2. The different subunits are expressed in a tissue and development-
specific manner (Hobbs AJ., 1997);(Giuili G, 1992). The chromosomal loci of the 
genes encoding isoforms of guanylyl cyclase and their ligands have been 
mapped in the human and/or
 the mouse (Table 2) and are unlinked and scattered 
  18throughout
  the genome, with notable exceptions. For the rat so far only the 
subunits α-1, α-2, β-1 and β-2 have been described. The amino acid similarity 
between humans and rat for the α-1 subunit is about 84% (chromosomal 
location: 2q31-q33), for the α-2 subunit, 90%, for the β-1 subunit, 99% 
(chromosomal location:  2q31-q33) and for the β-2 subunit 81% (chromosomal 
location:  5q36) (Denninger JW, 1999).  
 
The most abundant
 subunits are α-1 and β-1, which are found in many tissues. 
Concomitant expression of both subunits
  is required for catalytic activity 
(Kamisaki Y, 1986);(Harteneck C, 1990);(Buechler WA, 1991);(Wedel B, 1995). 
These subunits
  were first cloned from rat and bovine lung (Koesling D, 
1988);(Koesling D, 1990);(Nakane M, 1990);(Nakane M, 1988). Depending upon 
the species, the molecular weight of the α-1 subunit ranges from 70-82 kDa and 
that of the β-1 subunit between 70-73 kDa. The rarer α-2 subunit (82 kDa) has 
been found to be expressed only in the human foetal brain (Harteneck C, 1991) 
and placenta (Russwurm M, 1998). sGC β-2 has never been found at the protein 
level; its mRNA was detected in rat kidney and in liver (Yuen PS, 1990).  
 
Although
  the  β-2 subunit can form a heterodimer with α-1, this holoenzyme
 
exhibits lower specific activity compared with α-1/β-1. Thus, NO-stimulation
 of 
COS-7 cells cotransfected with α-1/β-1 resulted in three times
  more cGMP 
production than in cells transfected with α-1/β-2 (Gupta G, 1997). Coexpression 
of  β-2 with α-1/β-1 decreased the formation
  of the α-1/β-1 heterodimer, 
presumably due to competition between
 β-1 and β-2 for binding to α-1. These 
data support the hypothesis
 that expression of β-2 may serve to regulate α-1/β-1 
sGC activity.
 In fact, expression of β-2 has been suggested to play a role in
 the 
pathogenesis of hypertension in the Dahl rat (Gupta G, 1997). The ~82-kDa α-2 
cloned from human fetal brain forms heterodimers
 with β-1 or β-2, but has lower 
affinity for β-1. Indeed, α-2/β-1 has
  a lower specific activity than α-1/β-1 
(Harteneck C, 1991). Two other subunits of human sGC, α-3 (82 kDa) and β-3 
  19(70 kDa),
 have been cloned from adult brain; however, later re-examination of 
sequence data revealed these isoforms as artifacts. Homodimerization of sGC α-
1 or sGC β-1 subunits has also been demonstrated, although the homodimers 
were inactive (Zabel U, 1999). An intriguing exception to this rule seems to be β-
2, which has been found to be active as a homodimer as determined in 
expression experiments in Sf9 cells (Koglin M, 2001). Recently AGAP1 (the 
prototype of an ArfGAP protein with a GTPase-like domain,
 Ankyrin repeats, and 
a pleckstrin homology domain) has been identified as a novel and specific 
interaction
  partner of sGC in vitro and in vivo (Meurer S, 2004). It has been 
demonstrated that AGAP1
 associates with both the α-1 and β-1 subunits of sGC 
and that complex
  formation between these proteins is modulated by tyrosine 
phosphorylation.
 Association with AGAP1 does not affect the enzymatic capacity
 
of sGC nor does it alter its NO sensitivity. It is possible that
 AGAP1, by binding to 
sGC, may help regulate the intracellular
 distribution of sGC and thus the local 
delivery of cGMP in mammalian
 cells. 
 
RNA splicing also contributes to the heterogeneity of sGC subunits. A variant of 
the α-2-subunit, α-2i, was identified in a
 number of cell lines and tissues by PCR 
using primers based on
  conserved sequences in the catalytic domain of 
mammalian guanylyl
 cyclase (Behrends S, 1995). The subunit α-2i is produced 
through
  alternative splicing of RNA that adds 31  amino acids to the catalytic
 
domain, with homology to a region within the catalytic domain
  of adenylyl 
cyclases. Previous studies demonstrated sGC catalyzed
 the conversion of ATP 
to cAMP (Mittal CK, 1977a). The region
 of homology in α-2i was postulated to 
increase the ability of this
  isoform of sGC to utilize ATP as a substrate and 
produce cAMP
 (Behrends S, 1995). However, coexpression of the α-2i/β-1 in
 Sf9 
cells abolished the ability of sGC to produce cAMP (Behrends S, 1995). In 
addition, Sf9 cells transfected with α-2i/β-1
 are devoid of guanylyl cyclase activity, 
whereas coexpression
 of α-2/β-1 results in production of cGMP in these cells, 
suggesting
 the α-2i-subunit can compete with α-2 for binding to  β-1 and act
 as a 
  20dominant negative inhibitor. Expression of this subunit may
  serve as a 
mechanism to regulate sGC activity in specific cells
 (Behrends S, 1995). 
2.2.2  Location of sGC genes 
The genes encoding human sGC subunits α-3 (equivalent to α-1) and β-3 
(equivalent to β-1) have been mapped to chromosome 4q32
  (Giuili G, 1993). 
Because both subunits are required in a
  1:1 stoichiometry for activity, their 
common chromosomal locus
  may imply a coordinated regulation of gene 
expression. The genes
 encoding α-1 and β-1 sGC subunits in the medaka fish 
are organized
 in tandem within a 34-kb span (Mikami T, 1999). The activity
 of the 
5'-upstream region of each of the medaka fish genes was
 analyzed using green 
fluorescent protein reporter constructs expressed
 in medaka embryos (Mikami T, 
1999). Although the α-1 upstream
  region promoted expression of green 
fluorescent protein, the β-1 5' region was insufficient, suggesting expression of 
the α-1 and
 β-1 genes is coordinated. However, the α-2 subunit, which also can
 
form an active dimer in vitro with β-1, is encoded by a gene on
 chromosome 
11  (Yu F, 1996). That α-2 and β-1 subunits dimerize
  under physiological 
conditions argues against the requirement
  for coordinated regulation of 
expression of α-1 and β-1 subunits
  (Russwurm M, 1998). The genomic 
organisation of these subunits has recently been characterised in mouse and 
was found to be similar to that in the medaka fish (Sharina IG, 2000). The α-1 
sGC gene is approximately 26.4 kb and contains nine exons, whereas the β-1 
sGC gene spans 22  kb and consists of 14  exons. Both mouse genes are 
localized on the third chromosome, band 3E3-F1, and are separated by a 
fragment that is 2% of the chromosomal length. Genomic DNA corresponding to 
the β subunit (GCS β) gene from Anopheles gambiae (Caccone A, 1999), and for 
both the subunits from Drosophila (Shah S, 1995) have also been cloned and 
sequenced and the gene structure has been described. 
  212.2.3  Structure of sGC 
A comparison of the primary structure shows that the subunits
 can be divided into 
three domains: a C-terminal catalytic domain,
 a central part, and an N-terminal 
region. The catalytic C-terminal
  domains of each subunit of NO-sensitive GC 
display the highest
 degree of homology (Wedel B, 1995). These domains are 
also very similar to
 the respective regions in the peptide-activated, membrane-
bound
 guanylyl cyclases and in the adenylyl cyclases (AC). The catalytic
 domains 
of AC and NO-sensitive GC are structurally closely related
  as shown by the 
functional expression of AC/GC heterodimers (Weitmann S, 1999) and the 
conversion of substrate specificity (ATP vs. GTP) by the mutation
 of only three 
amino acids (Sunahara RK, 1998). 
 
Figure 5: Domain structure of soluble guanylyl cyclase (sGC). sGCs are 
heterodimers possessing amino terminal regulatory domains containing a heme 
prosthetic group with a ferrous (Fe
2+) core that forms an imidazole axial bond 
with His-105 of the β-subunit. In addition, sGCs possess homodimeric domains 
and carboxyl terminal catalytic domains that form one active and one inactive 
catalytic site (Lucas et al., 2000). 
  22The central regions preceding the catalytic domains show considerable
 homology 
to the membrane-bound enzymes (Wilson EM, 1995). In analogy, these
 regions 
are probably involved in the dimerization of the subunits,
  although detailed 
investigation is still missing. Recently there has been evidence that the 
dimerization region of β-1 extends over 205 residues of its regulatory and central 
domains and that two discontinuous sites of 41 and 30 residues, respectively, 
facilitate binding of β-1 to the α-1 subunit of sGC (Zhou Z, 2004). 
 
The N-terminal regions of the subunits of NO-sensitive sGC comprise
 the heme-
binding domain. NO-sensitive sGC is a hemoprotein and presence of the 
prosthetic
  heme group is mandatory for the activation of the enzyme by
  NO 
(Craven PA, 1978);(Ignarro LJ., 1990). Removal of the heme group abolishes 
NO-induced activation,
  which can be restored after reconstitution of NO-
insensitive sGC
  with heme (Ignarro LJ, 1986);(Foerster J, 1996). The heme 
stoichiometry has been agreed to be
 one mole per mole sGC heterodimer. Both, 
the α and β subunits are required for proper
 binding and orientation of the heme 
group. Sequential truncation
  showed that the subunits contribute unequally to 
heme binding
  with the α-1 subunit playing a more important role (Koglin M, 
2003);
 in addition, homodimers of the N-terminal part of the β-1
 subunit (the first 
385 amino acid) expressed in bacteria were
 shown to bind heme in a manner 
similar to the wild-type enzyme (Zhao Y, 1997).
  A histidine
  residue (His-105) 
within this region of the β-1 subunit
 was shown to bind to the heme iron, thereby 
acting as the proximal
 ligand. Deletion of His-105 has been shown to abrogate 
NO activation
 of the enzyme (Wedel B, 1994). Mutation of this histidine led
 to the 
generation of an NO-insensitive, heme-depleted enzyme
 with intact basal activity. 
In addition, two conserved cysteines
 adjacent to the His-105 on the β-1 subunit 
appear to
 play a role in the formation of the proper heme pocket. Mutation
 of 
these residues led to loss of enzyme-bound heme and NO responsiveness,
 
which could be regained after heme reconstitution (Friebe A, 1997). 
 
  232.2.4  Activators of sGC 
Already in the 1970s, NO-releasing compounds were found to be
  potent 
activators of sGC (Arnold WP, 1977);(Bohme E, 1978). Similarly, 
nitrovasodilators
 like glyceroltrinitrate or isosorbid dinitrate therapeutically
 used 
for the treatment of angina pectoris and coronary heart disease act by stimulation
 
of the enzyme. These nitrates do not release NO spontaneously;
 instead, they 
have to undergo bioactivation that either yields
 NO, nitrosothiols, or another sGC 
activating NOx species. 
 
Despite the stimulatory effect of these NO-containing compounds,
  the 
physiological significance of NO-induced activation of the
  enzyme did not 
become apparent until the identification of endothelium-derived
  relaxing factor 
(EDRF) as NO (Palmer RM, 1987);(Ignarro LJ, 1987). Formation of EDRF had 
been
  shown to occur in endothelial cells in response to vasodilatory
  agonists 
such as acetylcholine, histamine, or bradykinin, leading
 to vasodilation via the 
activation of NO-sensitive sGC in smooth
 muscle cells (Forstermann U, 1986).
 
After the discovery of NO in the vascular system,
 NO formation was reported to 
occur throughout the body (Moncada S, 1995). The
 enzymes responsible for the 
synthesis of NO were identified
 and termed NO synthases of which three major 
isoforms are known to
 date. The inducible isoform produces relatively high NO 
concentrations
 and thereby exhibits direct toxic effects. The enzyme is mainly
 
expressed in macrophages and plays a role in the nonspecific
 immune response. 
The neuronal and endothelial NO synthases are
  constitutively expressed 
enzymes that are regulated by the intracellular
  calcium concentration. The 
endothelial NO synthase is also activated
 by Akt/PKB-dependent phosphorylation 
triggered by shear forces
 exerted on the endothelial cells (Dimmeler S, 1999).
 
Both isoforms produce relatively
  low NO concentrations (1 to 100 nmol/L). At 
these low concentrations,
 NO functions as a signaling molecule, and most of its 
effects
 are mediated via the activation of NO-sensitive sGC.
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assumed that in the NO free state, iron is pentavalent and bound to histidine-105 
of sGC α-1. After NO binding, the iron-histidine bond breaks, which produces 
conformational changes in the sGC molecule and subsequently enzyme 
activation (Koesling D., 1999). Indeed, by recording of spectral profiles of sGC 
before and after NO addition, the changes in iron coordination and the break of 
the iron-histidine bond were confirmed (Schelvis JP, 1998);(Sharma VS, 1999). 
The essential role of this bond break was confirmed by the observation that 
another heme-binding molecule, CO, is a weak sGC activator. Unlike NO, CO 
does not break the iron-histidine-105 bond but evokes hexavalent ligation of iron 
(Stone JR, 1994);(Burstyn JN, 1995). It is assumed that the failure of CO to 
break the iron-histidine bond is the reason for its weak sGC-activating potency. 
However, combined action of CO and another NO-independent sGC activator, 
YC-1 (see below), results in activation of sGC comparable to that of NO without 
loss of 6-coordinated state of heme (Stone JR, 1998);(Denninger JW, 2000).  
 
Additional evidence for the role of heme interaction with the protein for sGC 
activation is the ability of protoporphyrin IX (PPIX), an iron-free heme, to 
stimulate hemedeficient sGC (Ohlstein EH, 1982). NO or CO do not stimulate 
heme-deficient sGC. Interestingly, YC-1 could potentiate the PPIX-stimulated 
sGC activity, but no shift of the concentration-response curve as seen with NO or 
CO was observed (Friebe A, 1996);(Friebe A, 1998a).  
 
Besides the well-established NO/heme-mediated stimulation, two
  novel 
mechanisms of activation have been identified for NO-sensitive
 sGC, indicating 
considerable therapeutic potential. First,
 the activator YC-1 (Figure 1 and 4) was 
shown to act as an "NO
  sensitizer," greatly enhancing the sensitivity of GC 
toward
 NO (Friebe A, 1996);(Friebe A, 1998a). Derivatives of YC-1 and other 
novel substances have
 been identified (Lee FY, 2001);(Straub A, 2001);(Stasch 
JP, 2002a);(Miller LN, 2003)
.  By increasing the NO responsiveness under
 
pathological conditions characterized by reduced NO release,
  these NO 
  25sensitizers may become important drugs in the treatment
  of various 
cardiovascular diseases. The effects of YC-1 on NO/cGMP signaling have been 
investigated
 in a variety of cells and tissues. In vascular smooth muscle
 cells, YC-
1 was reported to increase cGMP levels and to induce
  a concentration-
dependent relaxation of endothelium-denuded
  rat aortic rings (Mulsch A, 
1997);(Wegener JW, 1997);(Galle J, 1999).
 Other tissues in which YC-1 induced
 
cGMP elevations include guinea pig trachea (Hwang TL, 1999), guinea pig colon 
(Hallen K, 2001), corpus cavernosum (Brioni JD, 2002), and pig urethra 
(Schroder A, 2002). In endothelial cells,
 the YC-1 induced cGMP increases were 
most pronounced as in these
 cells YC-1 did not only stimulate NO-sensitive GC 
directly but
  also potentiated the stimulatory effect of the endogenously
 
synthesized NO (Wohlfart P, 1999). In platelets, YC-1 was shown to inhibit 
adhesion and aggregation (Wu CC, 1995);(Teng CM, 1997);(Friebe A, 1998b).
 In 
these cells, YC-1 led to a drastic, over 1000-fold increase
  in cGMP in the 
presence of NO. Closer analysis revealed that
  YC-1 applied in higher 
concentrations (10-100 µM) inhibited various PDEs (Friebe A, 1998b);(Galle J, 
1999). Due to the high catalytic
 rate of PDEs, some of the YC-1 effects observed 
in intact cells
 may be additionally caused by the inhibition of PDEs rather than 
solely by
 the stimulation of NO-sensitive GC. 
 
A second novel mechanism of activation has been shown to occur
  using the 
substance BAY 58-2667 (fig. 1 and 4) (Stasch JP, 2002b). This compound, an 
amino dicarboxylic
  acid, alone led to a moderate activation of sGC;
  this 
stimulation was additive to that of NO, which is in contrast
 to the potentiation 
seen with YC-1. Surprisingly, BAY 58-2667
  stimulated the heme-oxidized or 
heme-depleted purified enzyme
 almost 200-fold. This indicates that BAY 58-2667 
may be able
  to substitute for the heme group or stabilize the heme-free
 
conformation; the occurrence of the heme-free form of NO sensitive
 GC under 
physiological conditions remains to be elucidated.
  Photoaffinity labeling and 
binding studies suggest binding of
  the compound to both subunits of NO-
sensitive GC.  
  26A great number of other substances have been considered as possible 
physiological sGC regulators. However, after discovery of the role of NO in sGC 
activation, many (if not all) of these effects could be explained via effects on NO 
bioavailability or stability. 
 
Figure 6: Pharmacological compounds acting on NO-sensitive-GC. YC-1 
and BAY 58-2667 are novel activators of NO-sensitive-GC that increase cGMP 
production independent of NO. YC-1 potentiates the stimulatory action of NO and 
thus serves as “NO sensitizer”: BAY 58-2667 preferentially activates the heme-
depleted form of the enzyme. ODQ, in contrast, inhibits NO-sensitive-GC by 
oxidizing the heme iron leaving basal enzyme activity intact (Friebe A, 2003). 
  27 
2.2.5 Inhibitors  of  sGC 
Several substances have been found to inhibit NO-sensitive GC.
 The quinoxalin 
derivative 1H-[1,2,4] oxadiazolo [4,3-a]-quinoxalin-1-one
  (ODQ; Figure 6) was 
shown to be a potent and selective inhibitor
 of NO-sensitive GC in brain slices 
(Garthwaite J, 1995). ODQ does not lead to the
  inhibition of the membrane-
bound guanylyl or adenylyl cyclases
 and interferes with the stimulation of NO 
synthase and other
 heme proteins only at about 100-fold higher concentrations 
than required for inhibition of sGC (Feelisch M, 1999). Therefore, ODQ
 
represents an important tool to discriminate cGMP-dependent
  and cGMP-
independent effects of NO. Inhibition of NO-sensitive
  GC by ODQ has been 
demonstrated in a variety of other cells
  and tissues (Abi-Gerges N, 
1997);(Brunner F, 1996);(Garthwaite J, 1995);(Moro MA, 1996). Studies with 
purified NO-sensitive
 GC revealed that ODQ binds in an NO-competitive manner 
and leads
 to an apparently irreversible inhibition of the stimulated enzyme
 leaving 
basal activity unchanged. Spectral analysis suggests
 oxidation of the heme iron 
as underlying mechanism of the inhibitory
 effect (Schrammel A, 1996);(Zhao Y, 
2000). The notion that the heme iron is the target of
 ODQ is confirmed by the 
finding that ODQ is not able to inhibit
  the stimulation of NO-insensitive GC 
induced by the iron-free
  protoporphyrin IX (Koesling D, 1999).
  A derivative of 
ODQ, NS 2028 (oxadiazolo(3,4-d)benz(b)(1,4)oxazin-1-one),
 has been published 
to have properties similar to those of ODQ (Olesen SP, 1998).
 
Other inhibitors such as methylene blue and LY-83583 show less
 specificity than 
ODQ and, eg, inhibit the olfactory cyclic nucleotide-gated
 ion channel
 (Leinders-
Zufall T, 1995)
 or interfere with NO formation and NO release
 from NO synthases 
(Mayer B, 1993); therefore, ODQ should be preferred as specific
 sGC inhibitor.
  
  282.2.6  Role of divalent cations  
sGC requires divalent metal cations for catalytic activity. Both Mg
2+ and Mn
2+ can 
maintain catalytic activity of sGC probably via binding to the catalytic site or 
forming a complex with nucleotide substrate (Me-GTP) (Frey WH 2nd, 
1977);(Mittal CK, 1977b). Interestingly, these two metals differ in their effects on 
basal and stimulated sGC activity. While Mg
2+ is required for maximal stimulation 
of sGC with NO, basal activity of the enzyme is higher in the presence of Mn
2+ 
(Craven PA, 1976);(Kimura H, 1976). Exact mechanisms of these different 
actions of both cations are unclear.  
 
Another interesting point in the regulation of sGC by divalent cations is the role of 
calcium. It has been demonstrated that Ca
2+ inhibits recombinant sGC (Parkinson 
SJ, 1999) and sGC purified from bovine lung (Kazerounian S, 2002). Inhibition of 
sGC by Ca
2+ in rat anterior pituitary cells has been also demonstrated (Andric 
SA, 2001). The mechanism of the calcium effect on sGC activity is not 
completely elucidated. Recently, sGC has been found to specifically bind Ca
2+, 
and the existence of two different binding sites for divalent cations on the enzyme 
has been postulated (Kazerounian S, 2002). Ca
2+ is able to inhibit purified sGC 
via binding to a high affinity-binding site in the concentration range that is in the 
physiological range of intracellular Ca
2+ concentration in activated cells (100 - 
500 nM). At a Ca
2+  concentration of about 10 µM the inhibition of sGC was 
complete, which was explained by the binding of Ca
2+  to a low affinity site 
(Kazerounian S, 2002). It has been also demonstrated that Mg
2+ was not able to 
prevent the binding of Ca
2+ to a high affinity-binding site and thus also partly 
reversed  Ca
2+-dependent sGC inhibition via displacement of Ca
2+  from a low 
affinity-binding site. Interestingly, Mn
2+ was able to prevent the inhibitory effect of 
Ca
2+ on sGC (Kazerounian S, 2002). Demonstration of Ca
2+-dependent inhibition 
of sGC is an intriguing observation, since cGMP serves in many cases as a 
negative regulator of the Ca
2+ concentration and the effects of these substances 
(Ca
2+ and cGMP) are very often antagonistic.  
  293  Regulation of expression of sGC 
There are many studies over the last several years showing that sGC expression 
can be finely regulated at the transcriptional and post-transcriptional level in 
different cell types.  
 
There is increasing evidence of a  developmental regulation of sGC, with the α-1 
subunit being expressed prenatally in the rat brain (Smigrodzki R, 1996) and 
changes in the expression pattern observed in rat heart during post-natal 
development (Behrends S, 2002). Developmental changes of sGC expression 
have also been observed in rat ovary, pulmonary arteries and lungs. A regulated, 
cell- specific pattern of sGC expression in the rat ovary has been observed and is 
consistent with roles for cGMP in modulating ovarian functions (Shi F, 2004). 
Inhaled NO is known to influence the contractile state of pulmonary arteries most 
likely by activation of sGC in smooth muscle cells and an increase in sGC 
immunoreactivity in endothelial cells and a reciprocal decrease in smooth muscle 
cells was observed with postnatal development (Behrends S, 2001). Pulmonary 
sGC is increased during the perinatal period, which suggests an important role 
for NO-cGMP signal transduction in the perinatal regulation of pulmonary 
epithelial function and bronchial tone (Bloch KD, 1997). 
 
The availability of NO plays an important role in regulation of sGC expression. It 
was demonstrated that NO donors reduce sGC levels in kidney medullary 
interstitial (Ujiie K, 1994) and smooth muscle cells (Filippov G, 1997). It was also 
demonstrated that agents inducing the expression of the constitutively active high 
output form of NOS, NOS-II, produce downregulation of sGC mRNA, protein, and 
activity levels (Papapetropoulos A, 1996a);(Takata M, 2001). 
 
The mechanism of sGC regulation by NO and participation of cGMP in this 
process seems to be not completely resolved. Filippov and co-worker have 
investigated the mechanism of this down-regulation of sGC. They demonstrated 
  30that reduction of sGC mRNA is mediated by a decrease in its stability, an effect 
that is cGMP dependent in smooth muscle cells (Filippov G, 1997). cGMP 
analogues or cGMP-elevating agents down-regulate sGC mRNA levels also in 
other cell types (Ujiie K, 1994);(Papapetropoulos et al., 1996);(Filippov G, 1997). 
However, cGMP-independent regulation of sGC protein levels in porcine 
endothelial and smooth muscle cells has also been observed (Ibarra et al., 
2001). 
 
Expression of sGC subunits have also been studied under conditions of low NO 
availability. Although animals in which NO production was impaired either by NO 
synthase gene knock-out (Brandes RP, 2000) or NO synthase inhibitor treatment 
(Rothermund L, 2000) showed an enhanced sensitivity towards vasodilator 
activity of exogenous  NO, aortic sGC content was not altered as compared to wt 
mice (Brandes RP, 2000).  
 
Cyclic AMP has consistently been found to down-regulate sGC levels in several 
tissues (Shimouchi A, 1993);(Papapetropoulos A, 1995);(Papapetropoulos A, 
1996b). In some of these studies the downregulation of sGC expression was 
blocked by the inhibition of PKA (Papapetropoulos A, 1996b). In cases were 
inhibition of PKA was unsuccessful cross talk between cAMP and cGMP 
pathways resulting in the elevation of cGMP might have accounted for decreased 
sGC protein. Since in some studies high concentrations of cyclic nucleotide 
analogues were used, the reciprocal modulation of endogenously produced 
cAMP and cGMP could not be excluded. 
 
There has been evidence that in various cells cAMP-eliciting agonists decrease 
the expression
 of sGC mRNA and protein (Shimouchi A, 1993);(Papapetropoulos 
A, 1995) by a destabilization of the
  sGC mRNA. This effect is mimicked by 
activation of the cGMP-signaling
  pathway, e.g. application of NO donors, 
stimulation of particulate
  guanyl cyclase by atrial natriuretic factor, and 
stimulation of
  cGMP-dependent protein kinase (PKG) by the stable cGMP-
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 (Ujiie K, 1994). There is a recent article
 on 
post-transcriptional regulation of the α-1 subunit of NO-sensitive
 sGC in rat aorta 
(Kloss S, 2003) from our laboratory. HuR (Human R, embryonic
 lethal abnormal 
visual [ELAV]-like RNA-binding protein) has been identified as a
 factor stabilizing 
sGC  α-1 mRNA. YC-1-induced activation of GC
  decreased HuR expression, 
thereby inducing rapid degradation
 of sGC α-1 mRNA and lowering α-1 subunit 
expression as a negative
 feedback response. 
 
In endothelial cells, however, where cGMP was without any effect on sGC 
expression, the cAMP-elevating agent forskolin was also able to decrease sGC 
protein levels, suggesting a more complex action mechanism (Ibarra et al., 
2001).  
 
Various additional factors seem to have an effect on sGC expression. The 
cytokine IL1-β and TNFα, can reduce the α-1 and β-1 expression in smooth 
muscle cells and brain cells (Pedraza CE, 2003);(Takata M, 2001). It was 
demonstrated in Wistar rats that dietary supplementation with the antioxidant 
vitamin E restores normal endothelial function, reduces vascular superoxide 
anion formation and increases the expression of the sGC in rats with heart failure 
(Bauersachs J, 2001). The treatment with the hormone 17β-estradiol reduced the 
α-1 and β-1 mRNA expression and protein level in the uterus of young mice 
(Krumenacker JS, 2001). In rat pheochromocytoma PC12 cells, nerve growth 
factor (NGF) led to a transcription- and translation-dependent decrease in sGC 
α-1 and β-1 subunit mRNA and protein levels (Liu H, 1997). In astroglial cells ß-
amyloid peptides appear to reduce
 sGC protein (Baltrons MA, 2002). 
 
It is conceivable
 that variation of sGC expression enables a cell to adapt to the 
amount of NO available under certain
  physiological or pathophysiological 
conditions. Nitrate-tolerance to vasodilation by nitroglycerin (NTG) is a 
pathological condition of reduced NO bioavailability, which commonly occurs 
following prolonged exposure to NTG. In support of this hypothesis ncreased 
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  vessels from NTG-
tolerant rats and rabbits (Mulsch A, 2001). 
 
Ageing and hypertension lead to reduced expression of sGC (Bauersachs J, 
1998);(Chen L, 2000);(Ruetten H, 1999). In agreement with this, impaired 
vasodilation in response to the NO donor sodium nitroprusside has been 
reported in hypertensive rats (Kloss S, 2000). High salt intake by spontaneously
 
hypertensive rats (SHR) led to a reduced vascular sGC content in the
  aorta, 
which was paralleled by impairment of the vascular relaxation
 response to NO 
donors (Kagota S, 2001).  
 
Reduced sGC β-1 and sGC β-2 mRNA levels have been found in kidneys of Dahl 
salt-sensitive rats (Gupta G, 1997). In contrast, an increase in sGC protein levels 
was observed in aortic tissue of hypercholesterolemic rabbits (Laber U, 2002), 
which was considered by the authors as a compensatory mechanism for reduced 
(probably via oxidative damage) NO-sensitive sGC activity. Similarly, increased 
sGC protein levels have been found in rat heart after myocardial infarction 
(Bauersachs J, 1999) and in rat lung under hypoxic condition (Li D, 1999).  
 
It should be noted that in many cases the exact mechanisms of sGC protein 
reduction are unknown. Moreover, in many studies sGC mRNA and not protein 
levels have been used to determine sGC regulation. It is speculated that changes 
in translation or transcription rate or destabilization of mRNA might play an 
important role for regulation of the protein amount (Pyriochou A, 2005).  
 
Another interesting but poorly investigated aspect in the regulation of sGC is 
protein-protein interaction. It is well known that this kind of interaction plays 
important role in regulation of different signalling proteins. An exciting example is 
NOS with more than 20 proteins regulating the enzyme (Nedvetsky et al., 2002). 
Heat shock protein 90 (Hsp90) was the first sGC interacting protein to be 
identified (Venema et al., 2001). The N-terminal region of the β-1 subunit 
  33mediates binding of the heterodimeric form of sGC to Hsp90. Hsp90 binding to 
sGC probably regulates the pool of active enzyme by affecting the protein levels 
of the two subunits (Papapetropoulos A, 2005). Protein interaction between CCT 
(chaperonin containing t-complex polypeptide) subunit eta and the α-1β-1 
isoform of sGC has also been reported. Findings suggest that CCTeta binds to 
sGC (Hanafy KA, 2004) and, in cooperation with some other factor, inhibits its 
activity by modifying the binding of NO to the heme group or the subsequent 
conformational changes. The multidomain protein AGAP1,
 the prototype of an 
ArfGAP protein with a GTPase-like domain,
  Ankyrin repeats, and a pleckstrin 
homology domain has been identified as another sGC interacting protein (Meurer 
S, 2004). AGAP1 binds
 through its carboxyl terminal portion to both the  α-1 and 
β-1 subunits
  of sGC. It is possible that there is a potential role of AGAP1 in 
integrating signals
 from Arf, NO/cGMP, and tyrosine kinase signaling pathways. 
Recently Hsp70 has been identified as a novel sGC-interacting protein 
(Balashova N, 2005) that is responsible for the sGC-activating effect, probably in 
association with other factors or after covalent modification. 
 
4  The mRNA stability regulating protein HuR  
The growth and development of eukaryotic organisms require that gene 
expression is regulated. Typically, this regulation is considered to occur at the 
level of DNA (differential transcription) or protein (selective degradation). 
However, gene expression can also be regulated at the level of mRNA. 
Posttranscriptional gene regulation occurs through alterations in translational 
efficiency and in mRNA stability (Ross J., 1995). Over the course of the last 15 
years, many different types of mRNA decay have been described which alter the 
stability of particular mRNAs in eukaryotes. Both the signals and proteins 
participating in these processes have been identified. Some act to degrade, 
whereas others selectively stabilize mRNA.  
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Figure 7. mRNA stability is determined by numerous cis-acting elements. 
Indicated above are decay processes that act on all mRNAs. Examples of decay 
signals found only in certain mRNAs are listed below. 
 
3’ untranslated regions UTRs often regulate decay. One well-studied example is 
the 3’ UTR of transferrin mRNA, where an instability element is located adjacent 
to stem-loop structures called iron-responsive elements (IREs), which are 
reversibly bound by an iron-regulatory protein (IRP) leading to mRNA 
stabilization at reduced levels of cellular iron. The best-studied instability element 
in mammalian messages is the ARE (AU rich elements) (Chen CY, 1995). AREs 
consist of multiple stretches of adenylate and uridylate residues and are present 
in the 3’ UTRs of many mRNAs, including those of growth factors, cytokines and 
lymphokines. Because of the importance of proteins encoded by ARE-containing 
mRNAs to normal and neoplastic cell growth, this element must be considered a 
pivotal gene regulatory target in vertebrate cells. 
 
Class I AREs, such as the c-fos ARE, contain one to three scattered copies of 
the pentamer AUUUA embedded within U-rich regions (Wilson T, 1988). Class II 
AREs, like the GM-CSF ARE, consist of at least two overlapping copies of a 
critical nonamer UUAUUUA(U:A)(U:A) also in the context of a U-rich region 
(Lagnado CA, 1994). Class III AREs, an example of which is the c-jun ARE, lack 
the hallmark AUUUA pentamer but signal degradation with U-rich (and possibly 
other unknown) sequences. mRNAs containing class III AREs, like those 
containing class I AREs, exhibit degradation intermediates with 30–60 
nucleotides of their poly(A) tail remaining.  
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In an effort to understand the mechanism and regulation of ARE-signaled mRNA 
degradation, a number of laboratories have looked for proteins that selectively 
bind AU-and U-rich sequences. At least 14, apparently distinct proteins have 
been identified in cell extracts by ultraviolet (UV)-crosslinking and gel-shift 
assays: AUBF (Malter JS, 1991), AU-A (Bohjanen PR, 1991), AU-B (Bohjanen 
PR, 1991), AU-C (Bohjanen PR, 1992), Hel-N1 (Levine TD, 1993), hnRNP D 
(Zhang W, 1993), hnRNP A1 (Hamilton BJ, 1993), hnRNP C (Hamilton BJ, 
1993), AUH (Nakagawa J, 1995), GAPDH (Nagy E, 1995), hnRNP A0 (Myer VE, 
1995), HuR (Ma WJ, 1996;Myer VE, 1997), tristetraprolin (Carballo E, 1998) and 
TIAR (Gueydan C, 1999). However, only two of these proteins, hnRNP D and 
HuR, have been demonstrated to alter the stability of ARE-containing mRNA in 
vivo. 
 
RNAs bound by HuR:  
RNA ARE  class 
B-adrenergic receptor  III 
Cyclin A  I 
Cyclin B1  I 
Cyclin D1  I 
c-fos I 
c-myc I 
HPV-16 late  III 
HPV-1 late  I 
Herpesvirus saimiri-encoded U RNA-1  II 
Herpesvirus saimiri-encoded U RNA-2  I 
Herpesvirus saimiri-encoded U RNA-5  I 
IL-3 II 
N-myc III 
Neurofibromin III 
p21 I 
Plasminogen activator inhibitor  I 
Tumor necrosis factor-a  II 
Vascular endothelial growth factor  III 
GAP-43 III 
 
HuR (or HuA) is a ubiquitously expressed member of the embryonic lethal 
abnormal vision (ELAV) family of RNA-binding proteins, (Ma WJ, 1996) originally 
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(Campos AR, 1985). Both gel shift and UV-crosslinking experiments have 
provided evidence that HuR binding parallels the in vivo ability of ARE 
sequences to direct mRNA degradation. However, overexpression of this protein 
does not enhance degradation, but rather stabilizes messages containing class I 
and class II (and to a lesser extent class III) AREs in transient transfection 
experiments (Fan XC, 1998a;Peng SS, 1998). Accordingly, most of the specific 
mRNAs bound by HuR in vitro contain class I or class II AREs. HuR appears to 
act by protecting the body of the message from degradation, rather than slowing 
the rate of deadenylation, in overexpressing cells (Peng SS, 1998). An 
alternative explanation for the stabilization observed in cells overexpressing HuR 
is that it is active in decay, but when overexpressed sequesters other factors 
needed for degradation. A HuR gene knockout should clarify this question. The 
finding that expression of antisense RNA to HuR increases the decay of ARE-
containing mRNAs, (Wang W, 2000) is consistent with HuR’s major role being to 
stabilize.  
 
Among other RNAs, there has been recent evidence that the expression of sGC 
is subject to post-transcriptional
 regulation by HuR (Kloss S, 2003). It has been 
shown that cGMP- and cAMP-eliciting
 agonists decrease HuR expression in rat 
aortic tissue and cultured
 rat aortic smooth muscle cells
 and, at the same time, 
decrease
 expression of sGC α-1 and sGC β-1 subunits. These findings
 indicate 
that HuR is not only an important factor controlling
 vascular gene expression, but 
is also subject to control by
 vasoactive factors that regulate cGMP and cAMP 
levels (Kloss S, 2003);(Kloss S, 2004). The findings suggest that chronic 
hypertension induces changes
 in HuR expression and activity, which account for 
decreased
 sGC expression and activity in the aorta of hypertensive rats (Kloss S, 
2005). 
 
Like other Hu-family proteins, HuR contains three classic RNA recognition motifs 
(RRMs). At least in the case of HuD, ARE recognition appears to be mediated by 
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tail. In transient transfection assays, deletion of RRM3 alone abolishes HuR’s 
ability to stabilize ARE-containing reporter mRNAs (Fan XC, 1998a). Although 
predominantly nuclear, HuR shuttles between the nucleus and the cytoplasm via 
a novel shuttling sequence, HNS (HuR Nucleocytoplasmic Shuttling), located in 
the hinge region between its second and third RRM (Fan XC, 1998a);(Fan XC, 
1998b). HNS is similar to the M9 shuttling sequence of hnRNP A1 but differs in 
several critical residues. The nuclear export receptor for HNS is not yet known. 
HuR’s ability to shuttle has led to the suggestion that HuR may initially bind 
mRNAs in the nucleus and accompany them into the cytoplasm, providing 
ongoing protection from the degradation machinery. Recent in vivo crosslinking 
experiments and gradient analyses established that HuR is capable of binding 
poly(A)+ RNA in both the nucleus and the cytoplasm (Gallouzi IE, 2000). These 
data are consistent with the observation that a substantial fraction of cytoplasmic 
HuR (~15%) is associated with polysomes (Gallouzi IE, 2000). 
 
In an effort to understand the intracellular interactions that regulate the activity of 
HuR in stabilizing ARE containing mRNA, several protein ligands to HuR have 
been identified and characterized (Brennan CM, 2000). They are SETa:b 
(Matsumoto K, 1993);(von Lindern M, 1992), pp32 (Malek SN, 1990) and acidic 
protein rich in leucine (APRIL) (Mencinger M, 1998). Three of these HuR ligands 
(SETa, SETb and pp32) had previously been identified as inhibitors of protein 
phosphatase 2A (PP2A) (Li M, 1996);(Saito S, 1999). PP2A is a multimeric 
serine:threonine phosphatase, affecting a diverse set of cellular functions 
including: cell cycle progression, DNA replication, transcription, splicing, 
development and morphogenesis (Millward TA, 1999). Deletion experiments 
suggested that the acidic tail of at least pp32 (and possibly these other HuR 
ligands) is required for their interaction with a region spanning the hinge region 
and third RRM of HuR (Brennan CM, 2000). Studies provide evidence for the in 
vivo interaction of HuR with its ligands and strongly suggest that these HuR 
  38ligands either increase HuR’s affinity for its target mRNAs or modulate HuR 
export from the nucleus. 
  39II Materials  &  Methods 
1 Materials 
1.1  Cell Culture Reagents 
Ham’s nutrient media was purchased from PAA Laboratories GmbH, Linz, 
Austria. Dulbecco’s Modified Eagle Medium (DMEM), Minimal Essential Medium 
(MEM), foetal calf serum (FCS), penicillin-streptomycin, and trypsin/EDTA were 
from GIBCO, Invitrogen Corporation, Grand Island, USA. Dulbecco’s phosphate 
buffer saline (PBS) and Hank’s buffered salt solution (HBSS) were purchased 
from GIBCO BRL, Life Technologies Limited, Paisley, Scotland. Foetal bovine 
serum was purchased from Biochrom KG, Berlin, Germany. Tissue culture flasks 
and dishes were from Nunc, Roskilde, Denmark. Disposable pipettes were 
purchased from Corning Incorporated, New York, USA. Bovine serum albumin 
(BSA) was from Sigma, Deisenhofen, Germany.  
 
1.2 Molecular  Biology  Reagents 
Effectene transfection reagent, QIAprep Spin miniprep kit, QIAGEN plasmid midi 
kit, PCR purification kit and gel extraction kit were purchased from QIAGEN, 
Hilden, Germany. Hybond nylon membrane and Taq DNA polymerase were 
purchased from Amersham Biosciences, Uppsala, Sweden. Electrophoresis 
grade agarose was purchased from GIBCO BRL Life Technologies Limited, 
Paisley, Scotland. Trizol and Superscript II Rnase H- reverse transcriptase were 
purchased from Invitrogen Life Technologies, Carlsbad, USA. Diethyl 
pyrocarbonate (DEPC) was purchased from Applichem, Darmstadt, Germany. 
The restriction endonucleases and T4 DNA ligase used were from New England 
Biolabs Incorporated, Beverly, USA. Pfu Turbo DNA polymerase was purchased 
from Stratagene, La Jolla, USA. Deoxynucleotides (dNTPs) were purchased from 
Carl Roth GmbH, Karlsruhe, Germany. 
  40The following plasmids were used in this thesis: 
 
pGL3-Basic 
The pGL3 luciferase reporter vectors provide a basis for the quantitative analysis 
of factors that potentially regulate mammalian gene expression. These factors 
may be cis-acting, such as promoters and enhancers, or trans-acting, such as 
various DNA-binding factors. The backbone of the pGL3 luciferase reporter 
vectors contains a modified coding region for firefly (Photinus pyralis) luciferase 
that has been optimized for monitoring transcriptional activity in transfected 
eukaryotic cells.  
 
pRL-TK 
The pRL-TK vector is intended for use as an internal control reporter and may be 
used in combination with any experimental reporter vector to cotransfect 
mammalian cells. It contains a cDNA (Rluc) encoding renilla luciferase, which 
was originally cloned from the marine organism renilla reniformis. The pRL-TK 
vector contains the herpes simplex virus thymidine kinase (HSV-TK) promoter to 
provide low to moderate levels of renilla luciferase expression in cotransfected 
mammalian cells.  
 
pLexA 
pLexA is used to generate fusions of the DNA binding domain with a target (or 
bait) protein. Fusion protein expression is controlled by the strong yeast ADH1 
(alcohol dehydrogenase) promoter. It can be propagated and selected for in E. 
coli and yeast. The HIS3 (Histidine) transformation marker is used for selection in 
yeast. 
 
pJG4-5 
pJG4-5 expresses cDNAs or other coding sequences inserted into the unique 
EcoRI and XhoI sites as translational fusions to a cassette consisting of the SV40 
(Simian Virus 40) nuclear localization sequence, the 88 residue acidic activator 
  41(activation domain), and the hemagglutinin epitope tag for the construction of 
fusion proteins. Fusion protein expression is under the control of the GAL1 
(galactose) inducible promoter. It can be propagated and selected for in E. coli 
and yeast. The TRP1 (tryptophan) transformation marker is used for selection in 
yeast. 
 
pSHI8-34 
pSHI8-34 carries the lacZ reporter gene under the control of eight LexA 
operators and the minimal TATA region from the GAL1 promoter. pSHI8-34 
exhibits zero transcriptional activity in the absence of a LexA-fused activator. 
pSHI8-34 can be maintained as an autonomously replicating plasmid in strain 
EGY48 or can be forced to integrate into the EGY48 genome. 
 
pGEX 
GST (glutathione-S-transferase) Gene Fusion System incorporates pGEX 
plasmids for inducible, high-level intracellular expression of genes or gene-
fragments as fusions with Schistosoma japonicum GST. Expression in E. coli 
yields fusion proteins in the cytoplasm with the GST moiety at the amino 
terminus and the protein of interest at the carboxyl terminus.  
 
pBSKS (BlueScript) 
Some useful features of pBluescript: there is a multiple cloning site inserted into 
the LacZ gene, so clones with inserts can be distinguished as blue versus white 
cells by staining using X-gal (5-bromo-4-chloro-3-indolyl-bD-galactoside). It has a 
T3 promoter on one end side and a T7 promoter on the other terminal end. Other 
features are 21 unique restriction sites in the multiple cloning region, blue/white 
color selection and double and single-stranded sequencing. 
 
  42The following E.coli strains were used: 
 
BL21 
F¨C ompT hsdS(rB¨C mB¨C) dcm+ Tet
r gal endA Hte [argU ileY leuW Cam
r] 
The BL21 series of E. coli hosts are often the first choice for protein expression. 
They are protease deficient and designed for high-level protein expression from 
T7 RNA polymerase-based expression systems. Derived from E. coli B, these 
strains naturally lack the Lon protease and are engineered to be deficient for the 
OmpT protease. The Lon and OmpT proteases found in other E. coli expression 
hosts may interfere with the isolation of intact recombinant proteins. 
 
DH5α 
F-  80dlacZ M15  (lacZYA-argF) U169 recA1 endA1 hsdR17 (rk-, mk+) phoA 
supE44  - thi-1 gyrA96 relA1 
DH5α is a well-known, versatile strain that can be used in many everyday-cloning 
applications. In addition to supporting blue/white screening, recA1 and endA1 
mutations in DH5α increase insert stability and improve the quality of plasmid 
DNA prepared from minipreps. 
 
HB101 
F–, thi-1, hsdS20 (rB–, mB–), supE44, recA13, ara-14, leuB6, proA2, lacY1, 
galK2, rpsL20 (strr), xyl-5, mtl-1 
HB101 cells are useful for cloning in vectors that do not require complementation 
for blue/white screening. The competent cells can be used for many standard 
molecular biology applications. 
  431.3 Biochemical  Reagents 
Acrylamide/bisacrylamide solution, ammonium persulphate, coomassie stain, 
ponceau-s stain, dithiothreitol, glutathione, β-mercaptoethanol, 
isopropylthiogalactoside, leupeptin, aprotinin, pepstatin, Triton X-100 and Tween-
20 were from Sigma, Diesenhofen, Germany. Molecular weight markers, Roti 
load 4X were from Roth, Karlsruhe, Germany. Sodium dodecyl sulphate and 
glycerol were from Merck, Darmstadt, Germany. 
 
1.4  Animal Species and Maintenance 
Male Wistar rats (300-400 gm)(Harlan Winkelmann, Borchen, Germany) were 
used. The animals were kept in 550x330x200 mm sized Makrolon cages (Erich 
Becker, Germany) on dust-free wood granules (Altromin, Germany). They were 
fed with the Altromin-Standard-Diet No. 1320 and tap water ad libitum. The 
ambient temperature of the animal room was between 21° - 25° C with a relative 
air humidity of 45 - 65 %. The area was lit up with neon lamps in a circadian light-
dark rhythm in the ratio 10:14 (7.00 – 17.00 o'clock). 
 
1.5 Cell  Lines 
RLF-6 cells (rat lung fibroblast cell line) were a kind gift from Prof. U. 
Foerstermann, Institute of Pharmacology, Mainz University. They were 
maintained in Ham’s nutrient medium F12 supplemented with 15 % foetal calf 
serum (FCS). 
COS-1 cells (monkey kidney cell line) were a kind gift from Dr. Stephen Gross, 
Institute of Biochemistry, Frankfurt University, and were cultured in DMEM and 
10 % FCS. 
Primary cultures of rat aortic smooth muscle cells were obtained as described 
below and were maintained in MEM with 10 % FCS and 1 % penicillin-
streptomycin. 
 
  441.6 Buffers  and  Media 
Media for Bacteria 
Luria-Bertani Medium (LB) 
grams per Liter  Constituents 
10 Bacto-Tryptone 
5 Bacto-Yeast  Extract 
10 NaCl 
20ug of Ampicillin per ml of LB medium for LB-Ampicillin medium 
Media for Yeast 
Yeast Peptone Dextrose Medium (YPD) 
grams per Liter  Constituents 
10 Yeast  Extract 
20 Peptone 
20 Dextrose 
 
SD/–Ura, SD/–His, SD/–Trp/–Ura, SD/–His/–Trp/–Ura, SD/–His/–Ura Medium  
 per Liter  Constituents 
6.8  Yeast Nitrogen Base 
300 ul  12.5 M NaOH 
2% Glucose 
700 mg  DO Supplement(–Ura, –His, –Trp/–Ura, 
–His/–Trp/–Ura, – His/–Ura) 
 
SD/Gal/Raf/–His/–Trp/–Ura, SD/Gal/Raf/–His/–Leu/–Trp/–Ura Medium  
 per Liter  Constituents 
6.8  Yeast Nitrogen Base 
300 ul  12.5 M NaOH 
2% Galactose 
1% Raffinose 
80 ul  X-Gal 
2 ml  BU Salt 
700 mg  DO Supplement(–Ura, –His, –Trp/–Ura, 
–His/–Trp/–Ura, –His/-Ura) 
 
Stocks for Yeast Media 
BU Salt 
per Liter  Constituents 
70 g  Na2HPO4• 7H2O 
30 g  NaH2PO4
 
  45X-Gal 
  Constituents 
1 ml  N,N-dimethylformamide (DMF) 
20 g  5-bromo-4-chloro-3-indolyl-b-D-
galactopyranoside (X-Gal) 
 
 
Buffers 
4x Laemmli-buffer  
per Liter  Constituents 
125 mM                                           Tris/HCl pH 6.8 
10% (w/v)                                        SDS 
50 mM                                             Dithiothreitol 
30% (v/v)                                        Glycerol 
0.01% (w/v)                                     Bromphenol blue 
 
10x PAGE  
per Liter  Constituents 
250 mM                                            Tris 
1% (w/v)                                           SDS 
520 mM                                            Glycine 
50x TBST  
per Liter  Constituents 
0.1 M           Tris pH 8.0 
1.5 M             NaCl 
5% (v/v)   Tween 20 
 
 
 
Transfer buffer  
per Liter  Constituents 
25 mM   Tris 
192 mM   Glycine pH 8.3 
20% (v/v)   Methanol 
 
 
  46Additional buffers and solutions 
10x PBS (pH 7.4)  
per Liter  Constituents 
1.3 M   NaCl 
30 mM   NaH2PO4
70 mM   Na2HPO4
 
50x TAE  
per Liter  Constituents 
2 M   Tris 
1 M   Acetic acid 
50 mM   EDTA 
 
10x TBE 
per Liter  Constituents 
0.45 M   Tris 
0.45 M   Boric acid 
10 M   EDTA 
 
 
1.7  Laboratory Equipments  
Gel dryer 583, Gel Doc 1000; Bio-Rad, Germany 
T Gradient Thermocycler, UV Photometer Gene Ray, Shaker Heater Incubator 
(Compact Line OV); Biometra, Germany 
Herasafe Clean Bench, Incubator Heraeus BBD 6220, Centrifuge Biofuge; 
Heraeus, Germany 
Sonicator; Gerhard Heinemann Labor, Germany         
Vortex  Genie2; Scientific Industries, USA 
Test tube thermostat; Roth, Germany 
Shaker GFL 3005; Orbital, Germany 
Luminometer LB953; EG & G Berthold,Germany 
Light Microscope; Carl-Zeiss, Germany 
  471.8 Computer  Programmes 
Microsoft Office 2000, Reference Manager 9, Adobe V, I-Photoshop 6, Scion 
Image 4.02, Corel Draw 5, were the softwares used. 
NCBI-Blast 
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&itool=toolbar)  
and Matinspector V2.2 
(http://www.genomatix.de/?s=78d4cce024079eadfd01775177277a4c)  
were used on the Internet.  
 
1.9 Statistical  calculations 
Statistical calculations were performed using GraphPad Prism 3.0 statistical 
package (GraphPad Software, San Diego, California, USA). Statistical 
differences between the means were analysed by Student’s unpaired t-test. For 
multiple comparisons, one-way analysis of variance (ANOVA) test was 
employed.  
  482 Methods 
2.1 Nucleic  Acid  Preparation 
2.1.1 Plasmid  Preparation 
The method employed for plasmid preparation was dictated by the purity and 
quantity of DNA required. 
2.1.1.1 Small-scale  Plasmid  Preparation from E.coli 
2 ml LB was inoculated with a single colony of the respective E. coli clone and 
incubated for 8-16 h at 37°C at 160 rpm. One ml each of the grown cultures was 
taken in a 1.5 ml eppendorf tube and centrifuged for 30 seconds at 10.000xg. 
The pellet was resuspended in 100 µl TE (50/10)/RNaseA (10 mg/ml in 50 mM 
potassium acetate pH 4.8, heat-inactivated) and cells were lysed with 200 µl of 
0.2 M NaOH/1% SDS. 200 µl of 3 M potassium acetate was added and 
centrifuged for 5 minutes at 10,000xg. The supernatant was transferred to a fresh 
tube, 500 µl isopropanol was added and centrifuged for 10 minutes at 10.000xg 
at 4°C. The resulting pellet was washed with 500 µl of 70% ethanol, centrifuged 
again for 5 minutes, air dried and dissolved in 20-50 µl of sterile water. 
High quality mini plasmid preparation was performed using the QIAGEN Plasmid 
Mini Kit. The protocol used was identical to the manufacturer’s instructions 
2.1.1.2  Large Scale Plasmid DNA Preparation from E.coli  
E.coli DH5α cells were transformed as described above. An individual colony 
was picked up from the LB plates or 50 µl aliquot was taken from glycerol stock 
and was inoculated in 5 ml LB medium (incubation overnight, 37°C, 160 rpm 
(Infors, Einbach, Germany). 100 -150 µl of this preculture was inoculated into a 
large culture with 50 ml LB-ampicillin medium (incubation overnight, 37°C, 160 
rpm). The culture was transferred in centrifuge tubes and pelleted at 6000xg, 30 
minutes and the plasmid DNA was prepared using the Qiagen Midi Plasmid 
Purification kit. Subsequently, the DNA was precipitated with 0.7 volumes of 
isopropanol and centrifuged at 15000xg for 30 minutes at 4°C. After air-drying 
  49the pellet, it was dissolved in 400 µl of sterile water, transferred into a 1.5 ml 
eppendorf tube and precipitated again by the addition of 2 volumes of 100 % 
ethanol, 1/10 volume of sodium acetate (pH 5.2) and 30 minutes incubation at -
20°C. After centrifugation (30 minutes, 12000xg, 4°C), the pellet was washed 
with 70 % ethanol (5 minutes, 12000xg, 4°C), air-dried, and redissolved in an 
appropriate volume of sterile water.The DNA yield was determined with the help 
of the UV spectrophotometer. The optical density (OD) was measured at 260 and 
280 nm (Biometra, Gottingen, Germany). As a check for impurities the quotient of 
the OD260/OD280 was also calculated, which should lie between 1.8 and 2.0 
(empirically found value). The plasmid DNA was then examined by running on a 
1% agarose gel. 
2.1.1.3  Small Scale Plasmid Preparation From Yeast 
Five ml of an overnight culture of yeast growing in  the specific selection medium 
was sedimented by centrifuging at 4000 rpm for 10 minutes. After decanting the 
supernatant, the pellet was resuspended in 30 µl of lyticase solution (10 mM Tris-
HCl pH 8, 1 mM EDTA, 4.5 units/ml Lyticase – filter-sterilised and stored at 4
0C) 
and incubated at 37
0C for 1 hour. 170 µl of the lysis buffer (10 mM Tris-HCl pH 8, 
100 mM NaCl, 1 mM EDTA, 2% Triton X-100, 1% SDS) was then added with 
brief vortexing. 200 µl glass-beads and 200 µl of phenol/chloroform mixture was 
added to the suspension and vortexed for 5 minutes at maximum speed. The 
tubes were then centrifuged at 13,000 rpm for 10 minutes. The top aqueous 
phase was transferred to a fresh eppendorf tube and the DNA precipitated with 
10 M ammonium acetate and 100 % ethanol. The tube was placed at –20
0C for 
at least 1 hour and then centrifuged at 13000 rpm for 10 minutes. The pellet was 
washed with 70% ethanol, air dried and dissolved in 20 ml H2O.  
  502.1.2  RNA Preparation  
Due to the susceptibility of RNA to degradation by RNAses  all solutions used 
were prepared with diethylpyrocarbonate (DEPC) water. DEPC treated water 
was obtained by adding 1 ml DEPC per litre of distilled water, incubating 
overnight at RT and then autoclaving it. 
 
RNA isolation was performed with Trizol reagent according to the manufacture’s 
instructions. Cells were grown and stimulated as described above. A pipette tip 
attached to a vacuum line removed last traces of media. Subsequently, cells 
were lysed with 1 ml of Trizol per 3 wells using 6-well-plates. In case of using 
isolated rat aorta, the tissue was frozen after stimulation and then homogenised 
in a tissue homogenator (B. Braun, Melsungen, Germany). 1 ml of the Trizol 
solution was added to every 100 mg tissue. The lysate was transferred into an 
eppendorf tube. After addition of 200 µl chloroform, the samples were inverted for 
30 seconds. The inverted tubes were stored at RT for 10 minutes and 
subsequently centrifuged (11000 rpm, 10 minutes at 4°C). Afterwards the 
aqueous upper phase was transferred into a fresh tube. RNA was precipitated 
using 500 µl of isopropanol and stored again for 10 minutes at RT. Finally a 
single centrifugation step was carried out at 13000 rpm for 15 minutes at 4°C to 
pellet the precipitated RNA. Then the RNA pellet was washed with cold 70% 
ethanol (with DEPC-treated water), followed by centrifugation (13000 rpm, 10 
minutes at 4°C). The final RNA pellet was resuspended in 20 – 25 µl DEPC-
treated water. After 10 minutes incubation at 55°C, the amount of isolated RNA 
was quantified photometrically. 
 
2.1.3 cDNA  Synthesis 
First strand cDNA synthesis was performed by incubating the following at 65
0C 
for 5 minutes in a nuclease free tube: 1 µl oligo (dT), 2 µg total RNA, 1 µl 10 mM 
dNTPs and MQ-H2O to 12 µl. The reaction mix was quickly chilled on ice before 
the addition of 4 µl 5X first strand buffer, 2 µl 0.1 M DTT and 1 µl RNAse out (40 
  51U/µl). The reaction mix was then incubated at 42
0C for 2 minutes before the 
addition of 1 µl (200U) of Superscript II. Incubation at 42
0C was carried out for a 
further 50 minutes followed by a 15-minute incubation at 70
0C (Biometra, 
Gottingen, Germany). The cDNA was then stored at –20
0C till required.   
 
2.2 Nucleic  Acid  Quantitation 
The concentration of DNA and RNA samples was determined by 
spectrophotometry at 260 nm  (Biometra, Gottingen, Germany). Each OD unit at 
260nm corresponds to 50 µg/ml of double stranded DNA and 40 µg/ml of RNA 
(Sambrook et al. 1989). 
 
2.3 Restriction  endonuclease digestion of DNA  
The digestion of DNA using the restriction enzymes was carried out in 
accordance with the manufacturer’s instructions. The standard reaction mix 
consisted of: DNA template, 10x stock buffer with a final concentration of 1x in 
the reaction mix, 1-10 units of the enzyme depending on the amount of DNA to 
be digested and H2O. These mixtures were incubated in a water bath at 37
0C for 
1-6 hours.  
  522.4 Agarose  gel  electrophoresis of DNA  
The DNA samples were mixed with 1/6 volume of the DNA loading buffer (6x: 
50% (v/v) glycerol, 0.01% (w/v) bromphenolblue, 0.01% (w/v) xyleneblue) and 
resolved in horizontal agarose gel electrophoresis at 40-120 V. The agarose 
concentration in the gel depended upon the size of the fragments to be 
separated [0.8-2% in 1x TAE (w/v)]. 1x TAE (40 mM Tris acetate, 1 mM EDTA) 
was used as the electrophoresis buffer. The gels were then stained in 0.1% 
ethidium bromide (EtBr) solution for 5 minutes and photographed under UV light 
(Fujifilm, Amersham Pharmacia). 
 
2.5 SDS  Gel  Electrophoresis 
Electrophoretic separation of proteins was carried out in the discontinuous buffer 
system for SDS polyacrylamide gels as originally described by Laemmli (1970). It 
was carried out using the Mini-Gel systems (Pharmacia Biotech, Uppsala, 
Sweden). Preparation of 8-15% separating gel and 5% stacking gel was done as 
following. 20 - 40 µg of total protein were diluted in 4x Roti Load1, boiled for 5 
minutes and loaded onto the gel. Prestained molecular weight markers were also 
loaded on each gel. Electrophoresis was performed at 100 V until the samples 
had reached the separating gel after which it was increased to 200 V. 
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Table 4: List of the composition of upper and lower gels in SDS 
electrophoresis. 
10x SDS Laemmli Running Buffer (0.25 M Tris, 1.92 M Glycine, 1% SDS, pH 8.3) 
Lower Gel: 4x Laemmli Lower Tris (1.5 M Tis, 0.4% SDS, pH 8.8) 
% Total Acrylamide:     8% 10% 12% 15% 
H2O    (ml)  12.1 10.5 8.75 6.25 
4x Lower Tris Buffer  (ml)  6.25  6.25  6.25  6.25 
29:1  Acrylamide:Bis  (ml)  6.67 8.35 10  12.5 
 
10%  APS  (l)  130 130 130 130 
TEMED  (l)  14 14 14 14 
Total Vol:     25 ml  25 ml  25 ml  25 ml 
 
 Upper Gel: 4x Laemmli Upper Tris (0.5 M Tris, 0.4 % SDS, pH 6.8) 
% Total Acrylamide:     5% 5% 
H2O   (ml)  5.8  11.6 
4x Upper Tris Buffer  (ml)  2.5  5 
29:1 Acrylamide:Bis  (ml)  1.7  3.33 
10% APS  (l)  40  60 
TEMED (l)  20  20 
Total Vol:     10 ml  25 ml 
 
  542.6  Electrophoretic Mobility Shift Assay(EMSA) 
Nuclear extracts from RLF-6 cells were prepared as described above. Binding 
was tested in 20 µl of solution by incubating 1-2 µg of nuclear extract with a 
biotinylated probe (MWG Biotech, Ebersberg, Germany) in reaction buffer {(10 
mM Tris, 50 mM KCl, 10 mM DTT) pH 7.5, 2.5% glycerol, 5 mM MgCl2} for 15 
minutes at 4
oC. For supershift assays, specific antibodies (Santa Cruz 
Biotechnology, Santa Cruz, USA) were added to the EMSA binding reaction 15 
minutes before the addition of probes and incubated on ice. The protein-DNA 
complexes were separated on a 8% non-denaturing polyacrylamide gel in ice-
cold 1x TBE buffer for 3 hours at 80 V. Gels were transferred onto Hybond-N+ 
nylon membranes (Amersham Biosciences, Uppsala, Sweden) by placing in 
between 3 layers of gel blotting paper (Schleicher and Schuell, Dassel, 
Germany) prewetted in 1x TBE Buffer in a semi-dry electroblotter (PeqLab, 
Erlangen, Germany) for 2 hours at 150 mA. The DNA was cross-linked to the 
membrane for 10-15 minutes with the membrane face down on a transilluminator 
equipped with 312 nm bulbs. After drying, the detection of the biotin labelled DNA 
was carried out using the LightShift Chemiluminescent EMSA kit (Pierce 
Biotechnology, Rockford, USA) according to the manufacturer’s protocol. Briefly, 
the membrane was incubated in the LightShift blocking buffer for 15 minutes in a 
clean tray on a shaker after which the buffer was replaced with the LightShift 
stabilised streptavidin-horseradish peroxidase conjugate diluted in the blocking 
buffer in a ratio of 1:300 and incubated for another 15 minutes. The membrane 
was washed 5 times for 5 minutes each with 1x wash buffer and incubated in the 
LightShift substrate equilibration buffer for 5 minutes. The LightShift 
luminol/enhancer solution and the LightShift stable peroxide solution were mixed 
in a ratio of 1:1 and added on to the membrane for 5 minutes after which the 
membrane was kept in a plastic wrap and excess solution was removed. The 
membrane was then placed in a film cassette and exposed to X-ray film. 
  552.7  DNA extraction from agarose gels 
DNA bands were visualised on a UV transilluminator, excised with a sterile 
scalpel, weighed, and then isolated from the gel using the QIAGEN gel extraction 
kit according to the manufacturer’s instructions. 
 
2.8  Amplification of DNA using the Polymerase chain reaction 
(PCR) 
PCR was used to amplify segments of DNA and was carried out in 0.2 ml thin-
walled PCR tubes. A typical 25 µl reaction mixture consisted of: 10-500 ng of 
template DNA, 10 pmol each of forward and reverse primers, 200 µM dNTPs, 1-2 
mM MgCl2, and H2O. Just prior to thermal cycling, 0.2 µl of the Taq DNA 
polymerase was added to the mix. Amplification was carried out in a T-gradient 
thermocycler. After the completion of the PCR cycles, products were 
electrophoresed on an agarose gel to determine the efficiency of amplification.  
 
2.8.1 Primer  Design 
Primers were produced by MWG Biotech, Ebersberg, Germany. The software 
indicated in Table 5 was used to check for specificity of the primers.  
 
Table 5: List of primers used for α-1 and β-1 sGC sequencing. 
Name    5´----  3´  Sequence     Position    
α1-sGC Forward  GAAATCTTCAAGGGTTATG    1527 – 1545*  
α1-sGC Reverse  CACAAAGCCAGGACAGTC    2352 – 2335*  
β1-sGC Forward  GGTTTGCCAGAACCTTGTATCCACC 1491–  1515+ 
β1-sGC Reverse  GAGTTTTCTGGGGACATGAGACACC  1775 – 1750+ 
eloII- Forward  GACATCACCAAGGGTGTGCAG   2039 - 2059† 
eloII- Reverse  GCAGTCAGCACACTGGCATA  2257 - 2256† 
 
* GenBank
®/EMBL Accession Number: M57405 
+ GenBank
®/EMBL Accession Number: M22562 
† GenBank
®/EMBL Accession Number: NM017245 
  562.8.2  Thermal Cycling Programme 
A basic thermal cycling program was employed for all PCRs conducted in this 
thesis. Firstly an initial denaturation step was carried out at 94
0C for 5 minutes. 
This was followed by 30-40 cycles of denaturation at 94
0C for 30 seconds, 
annealing at 50-60
0C for 45 seconds depending on the primers used and 
elongation at 72
0C for 30-120 seconds dictated by the length of DNA to be 
amplified. A final elongation step was carried out at 72
0C for 15 minutes. The 
PCR products were electrophoresed on an agarose gel and purified as 
mentioned above. 
 
2.9  Ligation of DNA  
A typical ligation mix consisted of 25-200 ng of the vector DNA, an appropriate 
amount of the insert DNA, 1x ligase buffer, 1 µl of the T4 DNA ligase and sterile 
H2O in a total volume of 10 µl. This mix was incubated in a water bath at 4
0C 
overnight or at room temperature for 2 hours and subsequently used to transform 
competent E.coli cells. 
 
2.10 Preparation  of Plasmid Vector 
In general, plasmids used for cloning were linearised with appropriate restriction 
enzymes, and dephosphorylated if compatible ends were produced. 
Dephosphorylation involved the addition of 2 µl of calf intestinal alkaline 
phosphatase (CIAP 1:40 in 1x phosphatase buffer), 6 µl phosphatase buffer and 
2 µl sterile MQ-H2O to a 50 µl plasmid digest. The reaction was incubated at 
37
0C for 30 minutes and 85
0C for 15 minutes. The dephosphorylated linearised 
plasmid was then analysed by gel electrophoresis and purified by gel extraction. 
  572.11  Transformation of E.coli cells 
2.11.1  Preparation of competent E.coli cells 
100 ml of LB medium was inoculated with an overnight culture of E.coli DH5α 
cells in a ratio of 1:100 and placed in a shaker-incubator at 37
oC. When the 
OD600 reached between 0.4 and 0.6, the cells were centrifuged (10 minutes, 
1500 g, 4°C). Subsequently, the cells were resuspended in 20 ml RF1 buffer 
(100 mM RbCl, 50 mM MgCl2, 30 mM potassium acetate, 10 mM CaCl2, 15% 
glycerin, pH 5.8) and kept on ice for 2 hours. After sedimentation of the cells by 
centrifugation, 4 ml RF2 buffer (10 mM MOPS, 10 mM RbCl, 75 mm CaCl2, 15% 
glycerin, pH 6.8) was added and incubated for 15 minutes on ice. This 
suspension of competent E. coli cells was kept in -70°C in 500 µl aliquots. 
2.11.2  Transformation of competent E. coli  
To 150 µl competent DH5α cells, approximately 1 µg plasmid DNA was added 
and kept on ice for 30 minutes. Heat shock was given by placing the mix in 42
oC 
water bath for 2 minutes, after which 600 µl of LB medium was added and 
incubated for 1 hour at 37
oC. 100 - 150 µl of the cell suspension was plated on 
LB Ampicillin plates and incubated overnight in the incubator at 37°C. 
 
2.12 Bacterial  frozen  stocks 
Frozen bacterial stocks of DNA clones were made by inoculating a single colony 
in 3 ml of LB medium containing the specific antibiotic. The culture was incubated 
overnight at 37
0C with shaking. Equal volumes of bacterial culture and 50% 
sterile glycerol were then mixed and frozen immediately at -70
0C. 
 
  582.13 Transformation  of  yeast 
A single yeast colony containing the appropriate plasmid was inoculated in 5 ml 
of the specific selective medium and incubated overnight at 30°C at 200 rpm. 10 
ml of YPD medium was inoculated with this overnight culture to an OD600 of 0.1-
0.2 and incubated at 30
0C with shaking for 3-5 hours until the OD600 reached 0.4-
0.8. 2.5 ml of the culture was harvested by centrifuging at 4000 rpm for 5 
minutes. The pellet was washed with 0.5 volumes of sterile H2O and centrifuged 
same as above. To the cell pellet was added in the following order: 45 µl sterile 
H2O, 240 µl 50% PEG-4000, 36 µl 1 M lithium acetate, 5 µl carrier DNA, 1-5 µg 
plasmid DNA. The suspension was vortexed for at least 1 minute and incubated 
at 30
0C for 30 minutes. Heat shock was performed by placing at 42
0C for 30 
minutes with mixing after every 10 minutes. The cells were collected by 
centrifuging and the resulting pellet was resuspended in 100 - 200 µl of sterile 
H2O, plated on the appropriate selection plates and incubated for 2 - 4 days at 
30
0C. 
 
2.14  Yeast mating assay 
Single yeast colonies from opposite mating strains were inoculated in 5 ml of the 
specific selective medium and incubated overnight at 30
0C at 200 rpm. A 1:5 
dilution of the cultures was prepared in YPD medium. For the mating, 250 µl 
each from both the yeast strains were mixed and incubated overnight at 30
0C. 10 
µl from each mating was placed on appropriate selection plates and incubated for 
2-4 days at 30
0C. 
 
  592.15  Cell culture  
2.15.1  Isolation of smooth muscle cells from rat aorta 
Rat aortic smooth muscle cells were obtained in primary culture. Thoracic section 
of aorta was dissected from male Wistar rats and kept in ice-cold HBSS. The 
aorta was cut open and the endothelium was removed with a cotton swab. The 
adventitia was then removed with fine forceps under a light microscope (Carl 
Zeiss, Jena, Germany). Aorta was cut into small pieces (1 x 1 mm) and 
transferred to 2 ml HBSS in which 1 mg/ml BSA, 380 U/ml collagenase 4 and 0.9 
U/ml elastase (Worthington Biochemical Corporation, Lakewood, USA) were 
added and incubated at 37°C for 30 minutes. Single cells were released by 
gentle triturating through a pasteur pipette. Cells were centrifuged at 800 rpm for 
4 minutes, washed once with HBSS and resuspended in MEM with 10% foetal 
calf serum (FCS) and 1% penicillin-streptomycin. The presence of smooth 
muscle cell population was confirmed by staining with monoclonal mouse anti-α-
smooth muscle actin–FITC conjugate antibody. 
2.15.2  Cell lines and media  
RLF-6 (fibroblast cell line) were a kind gift from Prof. U. Förstermann, 
Pharmakologisches Institut der Universität Mainz. They were maintained in 
Ham’s Nutrient Medium F12  supplemented with 15% foetal calf serum. 
 
COS-1 cells (monkey kidney cell line) were a kind gift from Dr. Stephen Gross 
and were cultured in Dulbecco’s Modified Eagle Medium (DMEM) and 10% FCS. 
2.15.3  Revival of frozen cells 
Cell line stocks were kept frozen under liquid nitrogen for long term storage. To 
revive cells, a frozen aliquot was thawed with 5 ml of prewarmed media by 
placing some of the media on top of the frozen cells and then sucking it up with 
the help of a 5 ml pipette. This was done repeatedly till the aliquot fully thawed 
after which they were transferred in centrifuge tubes and another 5 ml of the 
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pellet was resuspended in 5 ml of media and the entire content was transferred 
to a 25 cm
2 flask and kept in a humidified incubator at 37
0C supplemented with 
5% CO2. 
2.15.4  Passaging and maintaining cells 
Passaging was carried out once the cells were confluent. Media, PBS and the 
trypsin-EDTA solution were prewarmed to 37
0C. For trypsinisation, media was 
aspirated from within the flask, the cells were washed with 5 ml PBS and the 
trypsin-EDTA solution was added (2 ml to 75 cm
2 flask or 1 ml to 10 cm petri-
dish). They were then placed in the incubator at 37
0C for 2-5 minutes. The 
enzymatic reaction was then stopped by adding 5 ml of the media with FCS, the 
cells were then transferred to a sterile centrifuge tube. Cells were sedimented at 
1000 rpm for 4 minutes, the pellet was resuspended in 10 ml of the media and 
then split in appropriate ratio in 75 cm
2 flasks or 10 cm petri-dishes. Fresh media 
changes were carried out every 2-3 days. 
2.15.5  Freezing cells for storage 
Cells were prepared for freezing by culturing to 80-90% confluency in a 75 cm
2 
flask. Trypsinisation was carried out as mentioned. The pellet was resuspended 
in a specific volume of media. To this, an equal volume of 20% DMSO in FCS 
was added, mixed and then aliquoted into labelled cryotubes. These tubes were 
placed at –80
0C for at least 24 hours before placing them for long term storage 
under liquid nitrogen. 
2.16 Transient  transfection of RLF-6 cells  
The Effectene method (Qiagen) was used for the transient transfection of 
plasmid DNA into RLF-6 cells. This method is based on the formation of micelles, 
which fuse with the cell membrane releasing the plasmid inside. 0.4 µg of the 
reporter constructs (firefly luciferase) was used for the transfection experiments. 
As a control for efficiency of transfection 0.1 µg of pTK renilla coding for renilla 
luciferase under the control of herpes virus promoter was also used. Cells were 
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transfected on the next day in accordance with the manufacturer’s protocol. After 
approximately 16 hours, cells were washed with PBS and starved for a further 24 
hours before stimulation. All transfections were performed in duplicate or 
triplicate. 
2.17  Transient transfection of COS-1 cells 
A modified and more simplified version of the DEAE-Dextran protocol was used 
for thr transfection of COS-1 cells. Cells were seeded at a concentration of 0.6 x 
10
5/ml 16 - 20 hours prior to transfection. On the day of transfection, cells were 
washed with PBS and were incubated with solution I (1 - 3 µg of the DNA to be 
transfected, 50 µg/ml DEAE-Dextran, 50 µg/ml chloroquine in serum free 
medium) at 37
0C for 2 and a half hours. The solution was thereafter removed, 
cells were washed with serum free media and then incubated with solution II 
(10% DMSO in PBS) for 2 minutes at room temperature. This was then aspirated 
and cells were washed with serum free media. An appropriate volume of the 
media with serum was then added and the cells were kept in the incubator till 
harvest. 
2.18  Decoy oligodeoxynucleotide (ODN) technique 
Double stranded ODN were prepared from complemetary single-stranded 
phosphorothioate-bonded oligos (obtained from MWG-Biotech, Ebersberg, 
Germany) by melting at 95
oC for 5 minutes followed by a cool-down phase of 3-4 
hours at ambient temperature. 10 nM of the various decoy ODN were transfected 
along with the reporter and the renilla constructs where required.  
2.19  Determination of Luciferase Activity 
In the DLR (Dual Luciferase Reporter) assay system, the activities of the firefly 
and renilla luciferases are measured sequentially from a single lysate. Upon 
completing the measurement of firefly luciferase activity (the "experimental" 
reporter), the firefly luminescence is rapidly quenched, with simultaneous 
activation of the renilla luciferase luminescent reaction (the "control" reporter 
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provide rapid quantitation of both reporters co-expressed in the lysates of 
transfected cells.  
 
The use of firefly (Photicus pyralis) luciferase as reporter gene involves the 
adenosine triphosphate (ATP) dependent oxidative decarboxylation of luciferin, 
producing light emission at a wavelength of 562 nm.  
  
Luciferin + ATP * O2 + Mg
2+  → Oxyluciferin + AMP+PPi + CO2 + Light↑ 
 
The light emitted achieves its highest intensity after approximately 0.3 seconds 
and fades away thereafter within few seconds completely. Therefore it is 
important to use a luminometer that injects the reaction-mix to the cell lysate and 
measures the quantitative luminiscence with high speed. 15 - 50 µl of the cell 
lysate was put in luminat tubes and placed in the luminometer. Thereafter the 
injection of the luciferase reaction-mix and the measurement of the light emission 
(relative light unit (RLU)) was performed by the luminometer. If the light emitted 
was outside the linear range, measurements were repeated with lesser cell 
lysate volume. After the first measurement, the solution was replaced with 
substrate to quantify the Renilla reniformis luciferase. This solution contained the 
necessary components for the renilla luciferase and blocked at the same time the 
activity of the firefly luciferase. This solution was then injected to the samples 
already measured and the RLU was determined. 
 
2.20 Preparation  of  protein  extracts for gelshift assays 
The protein extraction protocol was adopted from the method as described by 
Schreiber et al. For the cytosolic extract, 200 µl of ice-cold Buffer A (10 mM 
Hepes pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5 mM 
PMSF, 5 µg/ml PIM) was added to approximately 10 mg of frozen tissue in 1.5 ml 
eppendorf tubes or 2 x 10
5 cells in culture dishes after washing once with ice-
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scraped with a cell-scraper (Greiner, Kremsmuenster, Austria) and transferred 
into 1.5 ml eppendorf tubes. 25 µl of 10% Igepal CA 30 was added to the 
suspension and vortexed for 10 seconds. The homogenate was centrifuged at 
13,000 rpm for 2 minutes and the supernatant was transferred to a new tube. 
This supernatant contained the cytosolic fraction. To the pellet, 50 µl of ice-cold 
buffer C (10 mM Hepes pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM 
DTT, 1 mM PMSF, 5 µg/ml PIM) was added, incubated in ice for 15 minutes and 
then centrifuged at 13,000 rpm for 15 minutes. The supernatant having the 
nuclear extract was transferred to a fresh tube and both the fractions were kept 
frozen at –80
oC until further use. 
 
2.21 Protein  estimation 
The protein content in extracts was estimated using the Pierce coomassie protein 
assay reagent (Pierce Biotechnology, Rockford, USA). This method is based on 
the fact that when coomassie  dye binds protein in an acidic medium, an 
immediate shift in absorption maximum occurs from 465 nm to 595 nm with a 
concomitant color change from brown to blue. Lysates where diluted with water 
in a 1:50 to 1:200 ratio. BSA in the range 0 - 25 µg/µl was used for the standard 
curve. The Pierce reagent was added in a ratio of 1:1 in a microtitre plate and the 
blue colour developed was measured spectrophotometrically by means of a 
microplate reader (Dynex Technologies, Berlin, Germany). 
 
2.22 Western  Blot  Analysis 
The protein samples were prepared and separated by SDS-PAGE as mentioned 
earlier. Proteins were transferred to a nitrocellulose membrane wetted with the 
transfer buffer (methanol 20% (v/v), Tris base 25 mM, glycine 192 mM) using a 
semi-dry electroblotter. It was used in accordance with the manufacturer’s 
instructions with protein transfer performed at 100 V for 1 hour. Protein transfer 
was assessed by the complete transfer of prestained low molecular weight 
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hours at room temperature in blocking buffer - TBST (25 mM Tris-HCl, pH 8.0, 
125 mm NaCl, 0.1% Tween 20) with 5% milk powder. This was then decanted 
and replaced with the primary antibody solution diluted appropriately in the 
blocking buffer. The membrane was incubated in this mixture overnight at 4
0C 
with gentle agitation. The membrane was then washed 5 times for 5 minutes 
each in TBST after which a horse-radish peroxidase conjugate was added to it 
appropriately diluted in the blocking buffer. After an incubation of 1 hour at room 
temperature with gentle agitation, the membrane was washed with TBST 5x for 5 
minutes. Bound antibodies were then detected on the membrane using ECL 
reagent in accordance with the manufacturer’s instructions. 
 
2.23 Immunoprecipitation 
COS-1 cells were transfected in 10 cm dishes with the plasmid for the over 
expression of the protein/s of interest, lysed in 1 ml ice-cold lysis buffer (1% 
Triton X-100, 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 50 mM NaF, 1 mM EDTA, 
0.1 mM EGTA, 1 mM Na3VO4, 0.5% deoxycholic acid, 0.1% SDS, 10 mg/ml 
aprotinin, 10 mg/ml pepstatin, and 20 mM phenylmethylsulfonyl fluoride) and 
sonicated (4 output control, 20% duty cycle, 3 x 5 seconds each) on ice. Cell 
debris were removed by centrifuging at 17000 rpm for 20 minutes at 4
0C. The 
supernatant was transferred to a fresh eppendorf tube and 50 µl from this was 
kept aside to check for the protein expression by SDS-PAGE and western blot 
analysis. The rest of the supernatant was divided into two eppendorf tubes and 2 
- 5 µl of the pre-immune sera or the specific antibody was added to each 
separately. The tubes were incubated at 4
0C for 1 hour on an end-to-end shaker. 
5 µl of Sepharose beads were then added to both and incubated again for 1 hour 
in the same conditions. The beads were collected by a brief centrifugation step 
and washed 3 times with lysis buffer. At the end of the last wash, the entire buffer 
was aspirated from the beads, 20 -30 µl of loading buffer was added and the 
proteins analysed by SDS-PAGE and western bloting. 
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The plasmid (pGEX) coding for the protein expressed as a GST-fusion was 
transformed in E.coli BL21. A single colony was inoculated in 5 ml of LB media 
with the appropriate selection marker and incubated overnight at 37
0C at 250 
rpm. Fresh LB media was inoculated with the overnight culture in the ratio of 1:25 
and incubated at 37
0C at 250 rpm. After 1 hour, the culture was induced with 
IPTG at a final concentration of 0.1 mM and incubated at 30
0C - 36
0C at 250 rpm 
for 2 - 4 hours. The cells were harvested and the GST fusion protein was bound 
to glutathione sepharose 4B beads according to the manufacturer’s protocol.  
 
2.25 GST-pulldown 
COS-1 cells were transfected in 10 cm dishes with the plasmid for the over-
expression of the protein of interest, lysed in 1 ml ice-cold lysis buffer (cf 
preceding passage) and sonicated on ice as described above. Cell debris was 
removed , the supernatant was transferred to a fresh eppendorf tube and 50 µl 
from this was kept aside to check for the protein expression by SDS-PAGE and 
western blot analysis. To 500 µl of the supernatant was added 5 µl of the 
glutathione sepharose 4B beads loaded with the GST fusion protein. The tube 
was incubated at 4
0C for 1 hour on an end-to-end shaker. The beads were 
collected by a brief centrifugation step and washed 3 times with ice cold PBS. At 
the end of the last wash, the entire buffer was aspirated from the beads, 20 - 30 
µl of loading buffer was added and the proteins analysed by SDS-PAGE and 
western blotting.  
 
2.26  Yeast interaction trap assay 
Yeast interaction trap assay vectors pLexA and pJG4-5 and yeast strains EGY48 
(MATα
  trp1 his3 ura3 leu2::6LexAop-LEU2 containing the reporter plasmid 
pSH18-34) and RFY206 (MAT a trp1::hisG his3 δ200 ura3-52
 lys2 δ201 leu2-3) 
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For mating, cell suspensions of both strains (50 µl each) were mixed and 
incubated in rich medium (YPD) at 30
0C for 14 - 16 h. Interactions were validated 
by growth and blue coloring on minimal agar plates lacking uracil, histidine, 
tryptophan, and leucine, supplemented with 2 % galactose, 1 % raffinose, and 80 
µg/ml 5-bromo-4-chloro-3-indolyl-D-galactopyranoside (X-gal). 
 
2.27 Spermidine/spermine  acetyltransferase activity 
20 µL of sample containing the desired concentration of SSAT-GST was put into 
chilled 1.5 mL eppendorf tube in duplicate. 30 µL 0.5M HEPES was used for the 
blank (lower limit of activity). 30 µL of reaction mixture (10 µL 0.5 M HEPES, pH 
7.8, 5 µL 30 mM spermidine, 0.5 µL [
14C]acetyl coenzyme A- (Amersham 
Biosciences, UK, in 14.5 µL dd H2O) was then added to each tube except the 
blank.  30 µL of the reaction mix was aliquoted into two scintillation vials for the 
TSC (total substrate count- upper limit of activity).  Tubes were vortexed and 
placed on rack of tubes uncapped in 37
°C water bath for 5 minutes. The rack was 
placed back on ice and 20 µL of 0.5 M hydroxylamine was added to each tube. 
Samples were boiled for 3 minutes. Whatman p81 filters (Markson Lab Sales, 
USA) were labeled with pencil for each sample and blank and placed on non-
absorbent surface material. 50 mL of each sample was placed onto each filter.  
The sample-soaked filters were placed into a wash system with a continuous 
slow-flow of distilled water for 30 minutes. Filters were removed and dried on 
Whatman #1 filter paper. Each filter/sample was placed into a scintillation vial, 
labeled, suspended in 5 mL non-aqueous counting fluid (Biosafe, USA) and each 
sample was counted for 1 minute. 
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1  Transcriptional regulation of sGC expression 
The 5' upstream
 region of the rat α−1 and the β−1 sGC genes had been isolated 
by rapid amplification of cDNA ends (RACE) and analyzed for promoter
 activity 
by using luciferase reporter constructs. Their transcriptional
 start sites had been 
identified by Dr. Meik Behrens in our laboratory in primary smooth muscle cells. It 
was clear that both genes are transcribed independently; however the regulation 
of each promoter remained to be elucidated. In order to determine the promoter 
region harboring the maximal basal activity, deletion constructs of the sGC α−1 
promoter were analysed for the reporter activity. The pivotal transcription factors 
responsible for the activity of this fragment were identified. However, to establish 
the transcriptional regulation of the gene, it was important to analyse the 
promoter response to an external stimulus and to investigate the contribution of 
the identified transcription factors. Various experiments were designed for this 
study the results of which are described in the following chapters. 
 
1.1  Basal activity of the promoter of sGC α-1 subunit in RLF-6 cells 
Genome walking from the 5’ UTR of the α−1 subunit resulted in different clones 
that were subsequently sequenced and cloned into the pGL3basic vector 
containing luciferase as reporter gene. For the α−1 subunit following clones were 
obtained Alpha3000 (with -2794 bp), Alpha1100 (-1092 bp), Alpha350 (-346 bp) 
and Alpha200 (-200 bp) (see fig. 8). 
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  Figure 8: The 5’ UTR of the rat sGC α−1 gene and deletional constructs. The 
deletion constructs were cloned into pGL3 vectors. Position of the identified 
transcriptional start site is indicated as +1.  
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Figure 9: Promoter activity of sGC α-1 deletion constructs in cultured rat 
aortic smooth muscle cells and RLF-6 cells. The constructs were transfected in 
the cells transiently and the reporter activities were determined. The firefly 
luciferase activity was normalised by the renilla luciferase activity. Transfections 
were performed in triplicate. Results are means ± SD (n=3) *, # P<0.05; ANOVA.  
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Figure 10: Promoter activity of sGC α−1 deletion constructs in RLF-6 cells. 
RLF-6 cells were transfected with luciferase reporter constructs containing 
different size promoter fragments and reporter activities were determined. The 
luciferase activity produced by the pGL3-basic or pGL3-Alpha-sGC was 
normalised by the luciferase activity produced by pRL-TK and are expressed in 
relative light units. Transfections were performed in triplicate. Results are means 
± SD (n=3) * P<0.05.  
 
The activity of the various deletion constructs of the α−1 sGC promoter was 
established in RLF-6 cells using luciferase reporter constructs and was found to 
be the same as in cultured rat aortic smooth muscle cells as observed by Dr. 
Meik Behrens in his doctoral thesis. However, the activity of the constructs were 
much lower (about five fold low) in smooth muscle cells as compared to the RLF-
6 cell line. This cell line consistently expresses high levels of the α−1/β−1 sGC 
heterodimer. Thus the rat lung fibroblast RLF-6 cell line was chosen as a cell 
model to investigate transcriptional activity in the subsequent experiments. 
Transiently transfected luciferase reporter constructs harboring 0.2-3.0 kb of α−1 
sGC upstream sequence were analysed for promoter activity. The Alpha200 
construct containing ~200bp upstream the transcription start showed highest 
level of activity (fig. 9, 10).  
  702  Identification of transcription factors responsible for the basal 
expression of α-1 subunit of sGC in RLF-6 cells 
We found that the short core promoter of 200 bp upstream the transcription start 
site exhibited the highest basal promotor activity in reporter assays. We 
hypothesized that this core promotor decisively controls constitutive expression 
of the sGC α−1 subunit. Therefore, we were interested to identify the 
transcription factors responsible for this basal activity, in order to provide a 
mechanistic basis for delineating potential signalling pathways, which could 
regulate transcription of sGC subunit. Therefore, the following experiments were 
designed to study the effects of inhibiting the binding of these on the short as well 
as the full-length promoter. Analysis of the 200 bp of the 5’ UTR of the α−1 gene 
was performed using the MATINSPECTOR V2.2 software and those transcription 
factors were included in the study which had a core similarity of 1:00 and matrix 
similarity of 0.95. The contribution of these transcription factors towards the basal 
regulation of the α−1 subunit of sGC was investigated by the following methods. 
 
2.1  Decoy oligonucleotide approach 
To investigate the various transcription factors binding to the promoter of sGC 
α−1, RLF-6 cells were transiently co-transfected with the Alpha200 construct and 
10 nM of the decoy oligonucleotides (ODN) for NFY (CCAAT binding protein), 
Sp1, CABL (C-abl binding protein) and MZF (myeloid zinc finger protein). These 
factors were used because these were found by in silico analysis as described in 
above. The sequences of the single-stranded ODN were as follows (Table 6): 
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and the last 4 bases are phosphorothioated for use as decoy) 
 
cablf pto - 5'-aaaaGGTTTTTGTTTTtaac-3' bp 2686 – bp 2715 
cablr-pto - 5'-gttaAAAACAAAAACCtttt-3'   
sp1f-pto - 5'-gcgaTTGGGCGGGGAGcagg-3' bp 2808 – bp 2827 
sp1r-pto - 5'-cctgCTCCCCGCCCAAtcgc-3'  
nfyf-pto - 5'-ggacAGCGATTGGGCGggga-3' bp 2803 – bp 2822 
nfyr-pto - 5'-tcccCGCCCAATCGCTgtcc-3'  
mzf1f-pto - 5'-attgGGCGGGGAgcag-3' bp 2811 – bp 2827 
mzf1r-pto - 5'-ctgcTCCCCGCCcaat-3'  
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Figure 11: Effects of the decoy oligodeoxynucleotides for NFY, Sp1, CABL 
and MZF on reporter gene expression of the Alpha200 construct in RLF-6 
cells. 10 nM of the oligos were co-transfected with the Alpha200 construct in 
RLF-6 cells. After a 24-hour incubation period in the absence of serum, the 
luciferase activity was measured and normalised to the renilla counts. 
Transfections were performed in duplicate. Results are means ± SD (n=3) 
*P<0.05; ANOVA. 
  72The promoter activity (reporter gene expression) of the Alpha200 construct was 
almost doubled by treatment of the cells with the Sp1 ODN, whereas treatment 
with the NFY ODN resulted in a significant decrease in promotor activity (fig. 11). 
These findings suggest that the transcription factors Sp1 and NFY play an 
important role in the regulation of basal sGC α-1 transcription. In contrast, 
Alpha200 promotor activity was not significantly affected by exposure of the cells 
to the MZF and CABL ODNs (fig. 11). 
 
2.2  Effect of core deletions on basal promoter activity 
To confirm that the NFY and Sp1 binding sites are crucial for α−1 sGC promoter 
activity, we introduced small deletions in the Alpha200 construct containing the 
200 bp fragment. We chose this fragment because it possessed maximal 
promoter activity. In addition, we determined the effect of these deletions on the 
promoter activity of the Alpha3000 construct, which would reveal the influence of 
the other parts of the promoter on core promotor activity. Putative binding sites 
for CAAT and Sp1 transcription factors were investigated. The cores of these 
transcriptional factor binding sites were deleted individually in the constructs via 
site-directed mutagenesis. Boxes in fig. 12 denote the deleted nucleotides. The 
core deletions did not introduce any new binding sites as confirmed by sequence 
analysis with MATINSPECTOR V2.2 software. Transcriptional activities of the 
generated mutant constructs were assessed in RLF-6 cells.  
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Figure 12: The proximal promoter sequence of the rat α−1 sGC gene. Letters 
in boxes indicate the core binding sites for NFY and Sp1. The oligo-
deoxynucleotides for EMSA for these factors are underlined. 
 
 
 
sp1_for - 5'-GGAGGACAGCGATTgggcggGGAGCAGGACTCCGTTCTC-3' bp 2800 – bp 2838  
sp1_rev - 5'-GAGAACGGAGTCCTGCTCCAATCGCTGTCCTCC-3'  
nfy_for - 5'-GGTTTGGAGGACAGCGattggGCGGGGAGCAGGACTCCG-3' bp 2795 – bp 2833    
nfy_rev - 5'-CGGAGTCCTGCTCCCCGCCGCTGTCCTCCAAACC-3'    
nfy2f - 5'-GATTGACAAGCCATTAGccaatCTGTTGAGAATGAGGAAG-3' bp 618 – bp 657  
nfy2r - 5'-CTTCCTCATTCTCAACAGCTAATGGCTTGTCAATC-3'    
gcf - 5'-CCTGACATGCACGCCACCccccccCACCACACACACCCACAC-3' bp 1270 – bp 1311  
gcr - 5'-GTGTGGGTGTGTGTGGTGGGTGGCGTGCATGTCAGG-3'    
 
Figure 13: ODN for site-directed mutagenesis. Forward and reverse primers 
for each transcription factor are shown. Letters in bold indicate the cores of 
binding sites for transcriptional factors NFY and Sp1 that were deleted in the 
reporter constructs.                                                    
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Figure 14: Effect of core deletions for NF-Y and Sp1 on the activity of 
Alpha200 and Alpha3000 constructs in RLF-6 cells. RLF-6 cells were 
transfected with the constructs either with or without the deletion, which were the 
controls. After incubation for 16-20 hours in the absence of serum, cell lysates 
were assayed for luciferase activity and compared (Controls=1 RLU. 
Transfections were performed in triplicate. Results  are  in  mean  ±  SD  (n=3)         
*, # P<0.05; ANOVA.  
 
The site directed mutations using the ODNs mentioned in fig. 13 resulted in the 
constructs Alpha200-NFY, Alpha200-Sp1, Alpha3000-NFY and Alpha3000Sp1. 
These constructs were used for transfecting RLF-6 cells after which they were 
incubated for a further 16-20 hours in the absence of serum. As seen in fig. 14, 
the constructs containing the deleted sites for NF-Y and Sp1 showed a significant 
decrease in constitutive promotor activity, implying that these transcription factors 
are crucial elements in the basal expression of the of sGC α−1 subunit.  
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2.3 Decreased  expression of sGC α−1 by inhibitors of DNA binding 
To investigate the effect of inhibiting the interaction of NFY and Sp1 transcription 
factors with the promoter on sGC α−1 mRNA expression, RLF-6 cells were 
treated with varying concentrations of genistein and mithramycin A for 16 hours. 
Total RNA was extracted and reverse transcription and polymerase chain 
reaction were performed. Genistein inhibits the binding of NFY to the CCAAT box 
possibly by phosphorylation of the NFY-B subunit (Zhou Y, 1998). Mithramycin 
binds
 to GC boxes and prevents sequential binding of Sp1 (Blume SW, 1991). 
Both genistein and mithramycinA induced a concentration-dependent decrease 
in the expression of the sGC α−1. Genistein 50 µM and mithramycinA 100 nM 
were chosen as the optimum concentration required to see a significant effect 
and were used for subsequent experiments (fig. 15). This finding also implied 
that both NFY and Sp1 have an activating effect in the full-length sGC α−1 
promoter.  
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Figure 15: RT-PCR . RLF-6 cells serum-starved for 12-16 hours were incubated 
with increasing doses of mithramycin A (MtA) and genistein (Gen) for 16-20 
hours. RNA was prepared and RT-PCR was carried out for sGC α−1. A) The 
PCR products were electrophoresed on a 1 % agarose gel and stained with 
ethidium bromide. B) Densitometric analysis was performed on the gel and the 
intensities of the fluorescent bands were determined and plotted on the graph.    
* P<0.05; ANOVA n=3. 
  772.4  Decreased promoter activity by inhibitors of DNA binding 
To investigate the importance of the interaction of NFY and Sp1 transcription 
factors with the Alpha200 promoter on its activity, RLF-6 cells were transiently 
co-transfected with Alpha200 construct and treated with genistein and 
mithramycinA in the absence of serum. A 16-hour treatment with 50 µM genistein 
inhibited the activity by 50 % whereas treatment with 100 nM mithramycinA, 
increased the activity by almost two-fold (fig. 16).  
 
To confirm that the effect of the inhibitors on the sGC α−1  expression is 
transcriptional, RLF-6 cells were transfected with the longest promoter construct 
Alpha3000, and similarly treated with 50 µM genistein and 100 nM mithramycinA 
for 16 hours before harvesting. Both the agents induced a significant decrease of 
the promoter activity by 50 % (fig. 17).  
 
The opposite effects of mithramycinA in the Alpha200 andAlpha3000 constructs 
indicates that there is another Sp1 binding site present in the full-length promoter 
construct which overcomes the activation of the Sp1 site in the Alpha200 region 
in response to mithramycinA. Thus we see an overall reduction in mRNA 
expression and full-length promoter activity as well. 
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Figure 16: Effect of the inhibitors of NFY and Sp1 (genistein and 
mithramycin) on the activity of the Alpha200 construct in RLF-6 cells. RLF-6 
cells were transfected with the Alpha200 construct and treated with 50 µM 
genistein and 100 nM mithramycin A for 16 hours in the absence of serum. Cell 
lysates were assayed for luciferase activity and compared with untreated 
controls. Transfections were performed in triplicate. Results are in mean ± SD 
(n=3) * P<0.05; ANOVA. 
 
To confirm that the effect of the inhibitors on the sGC α−1  expression is 
transcriptional, RLF-6 cells were transfected with the longest promoter construct 
Alpha3000, and similarly treated with 50 µM genistein and 100 nM mithramycin A 
for 16 hours before harvesting. Both the agents induced a significant decrease of 
the promoter activity by 50 % (Fig. 23).  
 
The opposite effects of mithramycin A in the Alpha200 and Alpha3000 constructs 
indicates that there is another Sp1 binding site present in the full-length promoter 
construct which overcomes the activation of the Sp1 site in the Alpha200 region 
in response to mithramycin A. Thus we see an overall reduction in mRNA 
expression and full-length promoter activity as well. 
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Figure 17: Effect of genistein and mithramycinA on the activity of 
Alpha3000 in RLF-6 cells. RLF-6 cells were transfected with Alpha3000 and 
treated with 50 µM genistein and 100 nM mithramycinA for 16 hours in the 
absence of serum. Cell lysates were prepared and the luciferase activity was 
measured and normalised to the renilla luminescence counts. Transfection was 
performed in triplicate. Results are in mean ± SD (n=3) * P<0.05; ANOVA. 
 
2.5  DNA binding sites for the transcription factors NFY/Sp1 
In order to identify proteins bound to the potential transcription factor binding 
sites found in the analysis of the sGC α−1 promoter, nuclear extracts from RLF-6 
cells serum-starved for 16-20 hours were analysed by EMSA using biotin labelled 
DNA sequences of binding sites for the respective transcription factors. The 
probes used contained the following regions upstream of the transcriptional start 
site for the NFY and Sp1 ODNs respectively and were biotinylated at the 5’ end:  
  80Table 7:  Biotin labelled probes used for EMSA for the Sp1 and NFY 
transcription factors. 
 
  sp1f-bio - 5'BIO-gcgattgggcggggagcagg-3' bp 2808 – bp 2827  
  sp1r-bio - 5'BIO-cctgctccccgcccaatcgc-3'    
  nfyf-bio - 5'BIO-ggacagcgattgggcgggga-3' bp 2803 – bp 2822   
nfyr-bio - 5'BIO-tccccgcccaatcgctgtcc-3' 
 
The EMSA clearly showed the formation of multiple complexes with the 
biotinylated ODN probes for NFY and Sp1 when incubated with RLF-6 nuclear 
extract (fig. 18), as can be seen in lanes 1. In order to reveal the presence of 
these transcription factors in the shifted bands an antibody directed against either 
Sp1 or NFY protein was co-incubated with the nuclear extract and the respective 
oligodeoxynucleotide probe. In the presence of the antibody, a new shifted band 
appeared, while the intensity of one of the shifted bands seen in the absence of 
antibody decreased. This so-called "supershift" was induced by interaction of the 
antibody with the transcriptionfactor-oligo-DNA complex. A gradually increasing 
supershift was observed on incubating the complexes with increased 
concentrations of the antibodies for NF-Y and Sp1 (lanes 2 and 3). This finding 
demonstrates that these transcription factors were present in the shifted band, 
indeed. This experiment provides evidence that both transcription factors are 
present in nuclear extract from RLF fibroblasts and can bind to the core region of 
the sGC α−1 promoter.  
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Figure 18: EMSA performed with 1 µg nuclear extract (NE) from RLF-6 cells 
incubated with 2 ng of the biotinylated NF-Y and Sp1 
oligodeoxynucleotides. A supershift (indicated by arrow) was performed by 
adding increasing concentrations of the respective antibodies. The complexes 
were separated on a polyacrylamide gel and transferred onto nylon membranes. 
The detection of the biotin labelled DNA was carried out using the LightShift 
chemiluminiscent EMSA kit. Representative EMSA from three experiments are 
shown. 
 
A gradually increasing supershift was observed on incubating the complexes with 
increased concentrations of the antibodies for NF-Y and Sp1 (lanes 2 and 3). 
This finding demonstrates that these transcription factors were present in the 
shifted band, indeed. This experiment provides evidence that both transcription 
factors are present in nuclear extract from RFL fibroblasts and can bind to the 
core region of the sGC α−1 promoter. 
  822.6  Specificity of the decoy approach for inhibition of sGC α−1 
promoter activity 
To examine the specificity of the consensus decoy ODN for NFY and Sp1, an 
electrophoretic mobility shift assay (EMSA) was performed with nuclear extract 
from RLF-6 cells transfected with 10 nM of these decoy ODN for 12 hours in the 
absence of serum and the respective biotinylated oligodeoxynucleotides. The 
bindings of NFY and Sp1 oligos were significantly reduced in the nuclear extracts 
from NFY and Sp1 decoy ODN treated cells respectively (fig. 19). This indicates 
that the abundance of the transcription factor was significantly reduced in nuclear 
extracts of cells transfected with the respective decoy ODN. Also, the decoy 
ODN treatment specifically reduced the binding capacity of the targeted 
transcription factor, not that of other transcription factors, i.e. the Sp1 binding, for 
instance, was not affected in NFY decoy ODN transfected cells and vice-versa. 
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Figure 19: Specificity of the decoy oligodeoxynucleotides. RLF-6 cells were 
transfected with 10 nM of the NFY and Sp1 decoy ODN and incubated for 12 
hours in the absence of serum. Nuclear extract was prepared and EMSA was 
performed with 1 µg of the extract and 2 ng of the respective biotinylated oligos. 
Untransfected cell lysate was used as the controls. Representative EMSA out of 
3 experiments is shown. 
 
2.7 Competitive  inhibition  of  transcription factor binding 
To demonstrate the specificity of the complexes formed, increasing 
concentrations of unlabeled NF-Y/Sp1 consensus oligos were added to the cell 
lysate and biotinylated NFY/Sp1 oligo. A reduction of the band intensities in the 
presence of a 5-fold excess of unlabeled consensus probe (fig. 20) was 
observed. This indicates that there was competition of binding of the transcription 
  84factors for labelled and unlabelled consensus DNA probes and with increased 
concentration of unlabeled oligo, lesser of the factors were binding to the 
biotinylated oligo; hence the reduction in intensity (fig. 20, lanes 2 and 3; lanes 5 
and 6). 
 
 
Figure 20: Competitive EMSA. 0.5 µg nuclear extract from RLF-6 cells serum-
starved for 16-20 hours were incubated with 2 ng of the biotinylated NF-Y and 
Sp1 oligos. Competiton for binding was performed by adding increasing 
concentrations of the respective unlabeled consensus oligos. The complex were 
separated on a polyacrylamide gel and transferred onto nylon membranes. The 
detection of the biotin labelled DNA was carried out using the LightShift 
chemiluminiscent EMSA kit. Representative of three independent experiments 
are shown here. 
 
  85With increased concentration of unlabeled oligo, lesser of the factors were 
binding to the biotinylated oligo; hence the reduction in intensity of bandshift was 
seen (Fig. 20, lanes 2 and 3; lanes 5 and 6). 
 
2.8  Reduction in enzyme activity by the inhibitors of DNA binding 
In order to check whether the decrease in the transcription level induced by 
inhibition of  binding of these transcription factors to the promoter resulted also in 
a decrease in the protein level of the sGC α−1 subunit and hence a decreased 
enzyme activity, RLF-6 cells were treated with genistein 50 µM and mithramycin 
A 100 nM for 16 hours. Thereafter, the cells were washed with PBS and 
isobutylmethylxanthine (IBMX, 0.5 mM) was added in order to prevent 
degradation of cGMP by cGMP-specific phosphodiesterases. 10 minutes later 
100 µM sodium nitroprusside (SNP) was added in order to maximally activate 
NO-sensitive sGC in these cells. After further 5 minutes the PBS was removed 
and the cells were denatured and lysed by adding 0.1 N HCl (0.5 ml per well). 
The cell lysates were evaluated for their cGMP content by enzyme-linked 
immunoassay (EIA, Amersham Biosciences). When stimulating maximally by 
NO, this is an estimate for the amount of functionally intact enzyme present in the 
cells. The activity of the treated cells were compared with the solvent-treated 
controls. The amount of cGMP detected (fmol/well) was normalized by the 
cellular protein content of the samples. As shown below the cGMP content of the 
cells was significantly reduced by both inhibitors (fig. 21), almost completely by 
genistein, and by about 40 % by mithramycin. This decrease in cGMP was not 
due to an unspecific toxic effect exerted on the cells, as verified by trypan blue 
staining and microscopic inspection. This experiment showed that chemicals 
interfering with the constitutive activity of the transcription factors NFY and Sp1 
reduced the content of functionally competent sGC, and furthermore showed that 
the level of the functional holoenzyme depends on the mRNA expression of the 
of the sGC α-1 subunit. 
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Figure 21: Effect of Genistein and MithramycinA on the cGMP content in 
RLF-6 cells. RLF-6 cells were treated with 50 µM genistein and 100 nM 
mithramycin A for 16 hours. The cGMP content was measured using Enzyme 
Linked Immunoassay. Incubations were performed in triplicate. The results are 
expressed as mean ± SD (n=3) * P<0.05; ANOVA. 
 
3  Effect of serum on sGC α-1 expression regulation  
NFY and Sp1 are instrumental in several physiological and pathophysiological 
effects mediated by several growth factors in smooth muscle cells. Sp1 plays an 
important role in the TGFβ mediated induction of integrins, which in turn is 
important in restenosis and atherosclerosis (Kintscher U, 2002). It mediates 
PDGF-induced p21 gene expression in VSMC which been shown to be a 
component of active cyclin/CDK complexes (Moon SK, 2003). Sp1 is also 
involved in the suppression of SMC differentiation marker gene expression in 
experimental atherosclerosis by PDGF (Wamhoff BR, 2004). NFY mediates 
PDGF induced Notch-3 receptor expression and signaling in vascular smooth 
muscle cells which has implications in cell-cycle regulation (Campos AH, 2002). 
Serum is considered to be a good source of many growth factors as TGF, PDGF, 
FGF, VEGF and EGF (Andreeva V, 2004);(Brown MR, 1991);(Chen SC, 1982). It 
would be possible that at least one of these NFY or Sp1 mediated processes by 
any one of the growth factors actually occurs involving the regulation of 
  87expression of sGC. Thus we decided to use serum as a stimulus to study the 
response of the sGC α−1 promoter. 
 
3.1  Serum downregulates sGC α−1 protein expression in rat aorta 
The effect of FCS on sGC α−1 protein expression was investigated by incubating 
isolated rat aortic segments (10 mm length) for 24 hours in culture medium 
supplemented with 10% FCS. 
 
A )        B) 
   
*
 
 
Figure 22: Effect of FCS on expression of sGC α−1 protein in rat aorta. 
Isolated segments of rat aorta were incubated for 24 hours with cell culture 
medium supplemented without (Control) or with 10% FCS. Cell lysate was 
prepared and a western blot was carried out for sGC α−1. A) Anti-α−1/β−1-sGC 
antibody was used as the primary antibody (1:400) and anti-chicken antibody as 
the secondary antibody (1:5000). B) Densitometric analysis was performed on 
the gel and the intensities of the bands were determined and plotted on the 
graph. Mean values ± SD from n = 3 * P<0.05. 
  88The effect of FCS on sGC α−1 protein expression was investigated by incubating 
isolated rat aortic segments (10 mm length) for 24 hours in culture medium 
supplemented with 10% FCS. Thereafter the aortic tissue was ground in liquid 
nitrogen by means of a pestle and mortar, the protein was extracted from the 
tissue powder by vortexing with hypotonic buffer solution (see Methods), and a 
western blot was performed for analysing sGC α−1 protein expression (fig. 22). 
The blot clearly showed a decreased expression (by one third) upon incubation 
with FCS as compared to organ incubation in its absence, indicating that FCS 
down regulated sGC α−1 expression. 
 
3.2  Serum downregulates sGC α-1 mRNA expression in RLF-6 and 
RASM cells 
A) 
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Figure 23: Effect of FCS on sGC α−1 mRNA expression in cultured rat 
aortic smooth muscle cells and RFL-6 cells. Cells were incubated for 24 hours 
in the absence (Control) and presence of 10% FCS. RNA was prepared (see 
Methods) and RT-PCR was carried out for sGC α−1. A) The PCR products were 
electrophoresed on a 1% agarose gel and stained with ethidium bromide. B) 
Densitometric analysis was performed on the gel and the intensities of the bands 
were determined and plotted on the graph. Mean values  ±  SD  from  n  =  3              
*, # P<0.05; ANOVA. 
 
In order to assess whether FCS decreases the expression of sGC α−1 also at 
the mRNA level, cultured rat aortic smooth muscle cells and RLF-6 cells were 
grown for 24 hours in the absence and presence of 10% FCS, the mRNA was 
extracted from the cell lysates, an RT-PCR for sGC α−1 mRNA was performed 
(see Methods) As illustrated in fig. 23 there was a clear reduction of mRNA 
expression in both the cell types following FCS incubation. This finding further 
lends support to our theory that growth factors present in FCS reduce the 
expression of sGC α−1. 
 
  903.3  Decrease in sGC α-1 promoter activity in response to serum 
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Figure 24: Effect of FCS on the activity of the truncated sGC α−1 promotor 
constructs in RLF-6 cells. RLF-6 cells were transfected with the sGC α−1 
Alpha200 and Alpha3000 constructs and cultured without or with 10% FCS for 
14-18 hours. Cell lysates were prepared and assayed for luciferase activity. 
Transfections were performed in triplicate. Results are in mean ± SD (n=3).               
*, # P<0.05; ANOVA. 
 
The effect of 10% FCS on the promoter activity of the sGC α−1 gene was 
investigated by transfecting RFL-6 cells with the Alpha200 and Alpha3000 
luciferase constructs and culture in the absence or presence of 10% FCS for 14-
18 hours. Cell lysates were then prepared and assayed for luciferase activity. A 
clear reduction in the reporter gene expression of both Alpha200 and Alpha3000 
constructs was observed upon FCS incubation (fig. 24). Thus, it was clear that 
FCS induced a down regulation of sGC α−1 by reducing its promoter activity. 
 
  913.4  Serum downregulation of sGC α-1 promoter is mediated by NFY 
and Sp1 
In order to identify the transcription factors involved in the promoter regulation by 
FCS, an EMSA was performed with biotinylated NFY- and Sp1-specific 
oligodesoxynucleotides and the nuclear extract from RLF-6 cells cultured for 24 
hours in the absence and presence of 10% FCS. There was an increased 
binding observed with the Sp1 probe (as indicated by the arrow), in contrast to a 
decreased binding with the NFY probe (Figure 31). Since the binding sites for 
NFY and Sp1 are overlapping in Alpha200, this implied that the presence of FCS 
increased the Sp1 binding and decreased the NFY binding to the site. Since we 
have observed that at this site, the binding of Sp1 leads to a decrease in 
promoter activity, hence we see a downregulation by FCS. 
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Figure 25: Effect of FCS on NFY and Sp1 transcription factor binding 
activity in nuclear extract of RFL-6 cells. 0.5 µg nuclear extract from RLF-6 
cells cultured with or without 10% FCS for 24 hours were incubated with 2 ng of 
the biotinylated NFY and Sp1specific DNA probes. The complex were separated 
on a polyacrylamide gel and transferred onto nylon membranes. The detection of 
the biotin labelled DNA was carried out using the LightShift Chemiluminiscent 
EMSA Kit. 
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4  HuR mediated downregulation of sGC 
The 3'-untranslated regions (UTR) of the sGC α−1
 and β−1 mRNA bear AU-rich 
elements (ARE), which are targeted by
  trans-acting factors for regulation of 
mRNA stability. One of
 these factors is the elav-like ubiquitous 34-kDa protein 
HuR,
  which binds to AREs, thereby protecting the respective mRNA
  from 
degradation (Fan XC, 1998a;Ma WJ, 1996). cGMP
 and cGMP-eliciting agents, 
such as YC-1, were found to decrease the expression
 of sGC α−1 mRNA via 
down-regulation of HuR (Kloss S, 2003). In accordance, it was observed that 
exposure of isolated rat aortic segments to the activator of
  adenylyl cyclase, 
forskolin, strongly reduced sGC α−1/β−1 and
 HuR protein and mRNA expression 
in a time-dependent and actinomycin
 D-sensitive fashion. Native
 protein extract 
from rat aorta shifted the electrophoretic mobility
 of biotin-labeled riboprobes from 
the 3'-untranslated region
  of sGC α−1 and β-1 mRNA, and these bands was 
supershifted by a monoclonal
  antibody directed against HuR.
  Forskolin 
decreased the HuR- sGC α−1/β-1 mRNA interaction and
 HuR protein expression 
in rat aorta, and this was prevented
 by the PKA inhibitory cAMP analog 3',5'-
cyclic monophosphorothioate,
  Rp-isomer (Rp-cAMPS). In cultured smooth 
muscle cells from rat
  aorta, forskolin induced a rapid increase in Fos/p-Fos 
protein
 levels and activator protein 1 (AP-1) binding activity. To finally prove that 
activation of AP-1 accounts for cAMP-induced
 down-regulation of HuR, we used 
a transcription factor decoy
 approach.  
 
4.1  Role of AP-1 in HuR mediated sGC downregulation 
In general, cAMP signaling to the nucleus is accomplished by
 translocation of the 
catalytic subunit of PKA into the nucleus,
 where it phosphorylates and activates 
activating (cyclic nucleotide
  responsive element-binding protein) and silencing 
(inducible
 cAMP early repressor) transcription factors (Eigenthaler et
 al., 1999 ), 
both of which can target cyclic nucleotide responsive
 element sites, such as in 
  94the c-fos promoter. It was observed that forskolin induced a very rapid increase 
in Fos and
 activated p-Fos that was accompanied by a transient
 activation of AP-
1, the heterodimeric transcription factor constituted
 by Fos and Jun.  
To prove that activation of AP-1 accounts for cAMP-induced
 down-regulation of 
HuR, we used a transcription factor decoy
  approach. RASMC starved for 24 
hours were
  pretreated (4 hour) or not with either an AP-1-cognate 
oligodesoxynucleotide
  (match ODN) or a mutated ODN (mismatch), and then 
incubated
 for 6 hour with solvent (0.1% DMSO) or forskolin (10 µM).
 The cells 
were harvested, and HuR expression was assessed by
  Western blotting. As 
shown, the down-regulation of
 HuR by forskolin was prevented by the match AP-
1 ODN, not by
 the mismatch ODN.
 
 
Figure 26. AP-1 decoy prevents forskolin-induced down-regulation of HuR 
in RASMC. Serum-starved (24 h) RASMC were exposed for 4 hours to 10 µM 
AP-1 oligodeoxynucleotide or a mutated ODN (mismatch, 10 µM), and then 
incubated for 6 hours with solvent (0.1% DMSO) or forskolin (10 µM). The cells 
were harvested, and HuR expression was assessed by Western blotting. The 
forskolin-induced decrease of HuR was prevented by AP-1 decoy, not by the 
mismatch ODN. Figure represents result from three experiments.  
  955  Identification of HuR Interacting Protein by Yeast Two Hybrid 
Analysis  
While investigating the transcriptional regulation of sGC α-1 subunit expression, 
efforts were also made to study the post-transcriptional regulation of sGC by the 
mRNA stabilizing protein, HuR. It has been established that HuR stabilises the 
sGC  α−1 and β-1 mRNA. However the pathway underlying this regulation 
remains unknown. In order to identify the mechanism of this regulation, we 
looked for HuR interacting proteins employing the yeast two hybrid assay. The 
yeast two-hybrid system is devised to identify genes encoding proteins that are 
physically associated with a given protein in vivo. The LexA Two-Hybrid System 
was used in this study wherein the DNA-BD (DNA-binding domain) is provided by 
the entire prokaryotic LexA protein, which normally functions as a repressor of 
SOS genes in E. coli when it binds to LexA operators. The AD (activation 
domain) is an 88-residue acidic E. coli peptide (B42) that activates transcription 
in yeast. Two different cloning vectors are used to generate fusions of these 
domains to genes encoding proteins that potentially interact with each other, and 
the recombinant hybrid proteins are coexpressed in yeast. An interaction 
between a target protein (fused to the DNABD) and a library-encoded protein 
(fused to the AD) creates a novel transcriptional activator with binding affinity for 
LexA operators. This factor then activates reporter genes having upstream LexA 
operators and this makes the protein-protein interaction phenotypically 
detectable. If the two hybrid proteins do not interact with each other, the reporter 
genes will not be transcibed. As a confirmation of the interaction outside the 
yeast cell, several assays are used, such as in vitro "pull-down" assays and co-
immunoprecipitation.  
  965.1  Construction of the "bait" 
To construct the LexA-fused
  bait protein, we amplified human HuR cDNA
 
(corresponding to residues 1-326 of the protein sequence)
 by polymerase chain 
reaction (PCR) using forward primer 5'-gcgaattcatgtctaatggttatgaa-3'
  with a 
flanking  EcoRI restriction site and reverse primer 5'-gctctcgagttatttgtgggactt-3'
 
with a flanking XhoI restriction site. pGEX-HuR was obtained from Dr. Stephan 
Kloess in our laboratory and was used as the template for HuR. The thermal 
cycling programme was followed as mentioned in Methods section; the annealing 
temperature was 50
0C for 45 seconds and the extension was carried out for 1 
minute at 70
0C. The fragment was first subcloned into pBSKS (fig. 27), verified 
for the sequence and finally inserted
 into the multiple cloning site  into the EcoRI 
and  XhoI restriction sites of pLexA (pLexA-HuR1-326). The yeast-two hybrid 
screening was carried out by using a human
 placenta cDNA library in the vector 
pJG4-5. 
 
 DB  vector 
selection marker 
(pLexA) 
AD vector 
selection marker  
(pJG4-5) 
Chromosomal 
reporter gene 
Plasmid 
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Figure 27: Construction of the “bait”. HuR was generated by PCR using 
pGEX-HuR as the template and purified by gel extraction. The fragment was first 
subcloned into pBSKS and verified for the sequence. The sequenced fragment 
was finally cloned into pLexA. 
 
5.2  HuR expression in yeast 
Before proceeding with screening, the actual expression of the fusion protein 
inside yeast was verified by SDS-PAGE and subsequent western blot analysis. 
After transformation of the plasmids encoding the fusion protein into 
Saccharomyces cerevisiae strain EGY48 and incubation on plates lacking the 
appropriate amino acids (e.g.Trp), single colonies were inoculated into 15 ml 
synthetic medium lacking the same amino acid(s). At an optical density (A600) 
around 0.7, the culture was centrifuged at 2500 rpm for 5 minutes; the pellet was 
washed in distilled water and boiled for 3 minutes in 200 µl of 4x Roti load buffer. 
50  µl of this sample was separated by 10% SDS-polyacrylamide gel 
electrophoresis and blotted onto a nitrocellulose membrane (Schleicher & 
Schuell, Dassel, Germany). Detection of the expressed fusion proteins was 
performed with polyclonal anti-LexA antibody and peroxidase-conjugated anti-
rabbit antibody using ECL (Amersham Life Science, Amersham, U.K.). The 
results showed that HuR was being expressed in the yeast cells (fig. 28).  
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Figure 28: Western Blot for HuR expression in EGY48. pLexA and pLexA-
HuR were transformed separately in yeast cells and the lysate was investigated 
for HuR expression using anti-LexA antibody (1:5000) and peroxidase-
conjugated anti-rabbit antibody (1:10000). Arrows indicate LexA (30 kDa) and 
HuR-LexA (62 kDa). M denotes the marker profile. 
 
5.3 Auto-activation 
Since the yeast two-hybrid system is based on reconstitution of a functional 
transcription factor, checking the auto-activation capacity of the target is crucial 
for the overall feasibility. To check for the auto-activation, the yeast interaction 
trap assay was carried out with pLexA-HuR1-326 and the empty activation domain 
vector pJG4-5. No growth and blue coloring was observed on minimal agar 
plates lacking uracil, histidine, tryptophan, and leucine, supplemented with 2% 
galactose, 1% raffinose, and 80 µg/ml 5-bromo-4-chloro-3-indolyl-D-
galactopyranoside (X-gal) indicating that there was no auto-activation. 
  995.4  Yeast-two hybrid screening 
Plasmids expressing human HuR fused to the LexA DNA binding domain were 
introduced in yeast strain EGY48. EGY48 containing pSH18–34 and pLexA-
HuR1-326 was
 transformed with the human placenta Matchmaker cDNA library
 and 
1 x 10
7 transformants were plated on selection medium (leu2).
 Colonies were 
screened by the ß-galactosidase reporter
  gene assay (lacZ) using X-gal (5-
bromo-4-chloro-3-indolyl-ß-D-galactoside)
 plates.  
 
Library plasmids of positive yeast clones (blue spots) were rescued
  by 
transformation of Escherichia coli KC8 strain. Generally, 3 colonies were picked 
up from each transformation and inoculated in LB-broth with ampicillin for 
miniprep of plasmids. Plasmid preparations obtained from the bacterial cultures 
were tested for the presence of the vector pJG4-5 containing the insert by 
restriction enzyme digests (fig. 29A & B). The resulting pattern of restriction 
fragments on the electrophoresis gel was compared to the pattern obtained by 
the digestion of the empty AD vector.  
 
 
Figure 29A: Screening of plasmids for the presence of inserts in pJG145. 
DNA obtained from positive coloured (blue) yeast colonies were transformed into 
E.coli KC8, plasmids were isolated and the DNA was digested with HindIII. 
Restriction fragment pattern was compared with the pattern of pJG145 digestion 
for the presence of inserts. M denotes the marker profile.   
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Figure 29B: Restriction digestion of plasmids selected from the above 
screening. 4 plasmids isolated from the yeast colonies showing a different 
pattern from pJG145 digestion were selected and tested again. From these, 
clones #2 and #4 were sent for sequencing for their identity. M denotes the 
marker profile. 
 
To test the
  specificity of protein–protein interaction, EGY48/pSH18–34
  was 
retransformed with the rescued library plasmids. The yeast
  reporter strain 
contained pLexA-HuR1–326 or empty
  pLexA as the bait. Transformants
  were 
assayed for leu2 and lacZ activity to reconfirm the interaction. Upon 
retransformation, only colonies from #2 and #4 turned out to be positive in terms 
of growth and blue coloration on minimal agar plates lacking uracil, histidine, 
tryptophan, and leucine, supplemented with 2% galactose, 1% raffinose, and 80 
µg/ml 5-bromo-4-chloro-3-indolyl--D-galactopyranoside (X-gal). DNA sequences 
of the two
 plasmids were determined by the dideoxy chain termination method
 
(MWG Biotech, Ebersberg, Germany). #2 was identified as Homo sapiens 
spermidine/spermine N1-acetyltransferase (SSAT) mRNA (accession No. 
NM_002970), #4 turned out to be a part of a vector that might have been used 
during the construction of the placenta library.  
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As a means to reconfirm the interaction by other approaches, 
immunoprecipitation was performed as mentioned in 2.23. Lysate of COS-1 
endogenously expressing HuR was prepared and 2 - 5 µl of the anti-rabbit 
antibody was added as the control and anti-SSAT antibody was added for 
immunoprecipitation. Western blot was performed using a monoclonal mouse 
anti-HuR antibody as the primary (1:400) and anti-mouse antibody (1:5000) as 
the secondary antibody.  
 
 
Figure 30: Immunoprecipitation assay. Immunoprecipitation (IP) from lysates 
of COS-1 cells endogenously expressing HuR, using anti-SSAT antibody. 
Western blotting (WB) was done with anti-HuR antibody (left). For control, anti-
rabbit antibody was used. 
 
The results clearly showed that SSAT and HuR were interacting at the in-vivo 
level; a strong HuR band was detected with anti-SSAT antibody as compared to 
the control. The anti-SSAT antibody was binding to SSAT which in turn interacted 
with HuR seen as a band in fig. 30. 
  1025.6 Construction  of  expression plasmids for SSAT 
For bacterial expression of identified interaction partner
 as GST fusion proteins, 
we amplified human SSAT cDNA
  by polymerase chain reaction (PCR) using 
forward primer 5'-gcgaattcatggctaaattcgtgatccg-3'
  with a flanking EcoRI 
restriction site and reverse primer 5'-gctctcgagtcactcctctgttgcc-3'
 with a flanking 
XhoI restriction site using pJG4-5-SSAT as the template. The thermal cycling 
programme was followed as mentioned in Methods section; the annealing 
temperature was 56
0C for 45 seconds and the extension was carried out for 90 
seconds at 70
0C. The fragment was first subcloned into pBSKS (fig. 31), verified 
for the sequence and finally excised by EcoRI and XhoI and ligated into pGEX 
previously
 modified for in-frame expression of EcoRI/XhoI fragments. E.
 coli BL21 
strain was transformed with recombinant pGEX plasmids,
  and GST fusion 
proteins from exponentially growing bacteria
  were purified by GSH-sepharose 
affinity chromatography according
 to the manufacturer’s instructions (Pharmacia). 
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Figure 31: Construction of Expression Plasmids for SSAT. A) SSAT was 
generated by PCR using pJG145-SSAT as the template and purified by gel 
extraction. B) The fragment was first subcloned into pBSKS and verified for the 
sequence. The sequenced fragment was finally cloned into pGEX. M denotes the 
marker profile. 
 
5.7 Confirmation  of  SSAT-HuR  interaction by GST-pull-down 
Another method to confirm the SSAT-HuR interaction was through GST-pulldown 
which was carried out as mentioned in 2.25. To the cell lysate from pGEX-SSAT 
transfected COS-1 cells, glutathione sepharose 4B beads loaded with the GST 
fusion protein was added. Western blot was performed and the protein was 
detected with anti-HuR antibody (1:400) and anti-mouse antibody (1:5000). 
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Figure 32: GST pulldown assay. GST-pulldown assay was performed with 
lysates of COS-1 cells transfected with SSAT-GST. Western blotting was done 
with anti-HuR antibody. For control, GST expressing cell lysate was used. 
 
This was an in-vitro approach to detect the interaction. The presence of a strong 
HuR band in the blot as compared to the control lane (fig. 32) clearly suggested 
that the interaction between HuR and SSAT happened in-vitro also.  
 
5.8 Preparation  of  deletion mutants of HuR 
 
 
Figure 33: Deletion mutants of HuR. The deletion constructs were cloned into 
pEG202/pLexA vectors. The size of the regions in terms of the number of amino 
acids and base pairs is shown by black (RRM1,2,3) and grey (Hinge) bars, 
respectively. The constructs were named pLexA-H1 through H4. 
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hinge region (fig. 33). Thus four constructs having each of them separately were 
generated from PCR using the following primers (Table 8): 
 
Table 8: List of the primers used for the PCR amplification of H1, H2, H3 
and H4 regions of HuR. 
 
For H1:  Forward - gcgaattcatgtctaatggttatgaa 
Reverse - gctctcgagtcatttgatcacctctgagc 
 
For H2:  Forward - gcgaattcatggaggtgatcaaagacgccaac 
Reverse - gctctcgagtcacacgtttttgttctgg 
 
For H3:  Forward - gcgaattcatgaacaaaaacgtggcactcc 
Reverse - gctctcgagtcagatgaaaatgcaccagcc 
 
For H4:  Forward - gcgaattcatgattttcatctacaacctggg 
Reverse - gctctcgagttatttgtgggacttg 
 
All the forward primers had a flanking EcoRI restriction site and reverse primers 
had a flanking XhoI restriction site. pLexA-HuR was used as the template. The 
thermal cycling programme was followed as mentioned in Methods section; the 
annealing temperature was 56°C for 45 seconds and the extension was carried 
out for 1 minute at 70
°C. The fragments were first subcloned into pBSKS verified 
for their sequence and finally excised by EcoRI and XhoI and ligated into pLexA  
(fig. 34). 
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Figure 34: Generation of deletion mutants of HuR. A) H1-H4 were generated 
by PCR using pLexA HuR as the template and purified by gel extraction. B) The 
fragments were first subcloned into pBSKS and verified for their sequence. C) 
The sequenced fragments were finally cloned into pLexA. M denotes the marker 
profile. 
  1075.9  Mapping of the interacting domain of HuR 
For mapping the domains of HuR which interact with SSAT, yeast trap interaction 
assay was carried out as mentioned in the Methods section. pJG4-5-SSAT and 
the different deletion constructs were transformed separately in the opposite 
strains of yeast. Cell suspensions from each (50 µl each) were mixed and 
incubated in rich medium (YPD) at 30
0C for 14-16 hours. Interactions were 
validated by growth and blue coloring on minimal agar plates containing X-gal.  
 
 
Figure 35: Mapping of the interacting domain of HuR. EGY48/pSH18–34
 was 
transformed with pJG-SSAT and full length or the deletion constructs of HuR and 
yeast interaction trap assay was performed. Interactions were validated by 
growth and blue coloring on minimal agar plates lacking uracil, histidine, 
tryptophan, and leucine, supplemented with 2% galactose, 1% raffinose, and 80 
µg/ml 5-bromo-4-chloro-3-indolyl-D-galactopyranoside (X-gal).  
  
  108The suspension carrying pJG4-5-SSAT and pLexA-H3 only turned blue whereas 
all the other three combinations of pJG4-5-SSAT with H1, H2 and H4 remained 
white (fig. 35). This clearly showed that only H3 region of HuR interacted with 
SSAT. H3 region of HuR is its hinge region (Fan XC, 1998b).  
 
5.10 Influence  of  HuR  on SSAT activity  
In order to characterize the functional implications of the HuR-SSAT interaction, 
studies were performed to check if they affected each other’s biological activity. 
SSAT is an enzyme of the catabolic pathway that acetylates 
spermine/spermidine. The activity of the enzyme was measured either alone or in 
combination of HuR through the SSAT activity assay, which measures the 
amount of 
14C-acetylated-spermidine. As shown in figure, HuR did not affect 
SSAT activity. 
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Figure 36.  Effect of HuR on SSAT activity. The SSAT activity assay was 
carried out with 250 ng of SSAT-GST, 30 mM spermidine and 0.5 µL [
14C]Acetyl 
Coenzyme A in the presence or absence of 250 ng of HuR. The reaction was 
stopped; the mixture was put on Whatman paper filters, dried and washed. The 
filters were then placed in the scintillation fluid and counted. The figure 
represents results from three independent experiments. 
  109  1105.11 Effect  of  SSAT on HuR binding to mRNA 
 
 
Figure 37.  Effect of SSAT on sGC-mRNA-binding activity of HuR. 
Biotinylated oligoribonucleotide from the 3’UTR of GC A-1 mRNA 
(DR_1GC3UTR2; 7.5 ng) was incubated for 30 minutes at 4°C with HuR in the 
presence or absence of 100-400 ng of SSAT-GST, and the EMSA was 
performed using an 8% TAE-polyacrylamide gel. Only GST was used as control 
for SSAT-GST. Figure represents result from three experiments. 
 
HuR is a ubiquitously expressed RNA binding protein that has been found to 
regulate the expression of sGC α-1 by binding to its 3’UTR mRNA. Since SSAT 
has been shown to interact with HuR, we performed an EMSA to see whether the 
HuR binding to sGC α-1 mRNA is affected in the presence of SSAT. Biotinylated 
oligoribonucleotide from the 3’UTR of sGC α-1 mRNA (comprising several AREs) 
was incubated with HuR (100 and 200 ng) with increasing concentrations of 
  111SSAT-GST (100-400 ng), and the mixture was analyzed by RNA-EMSA as 
described in Methods. HuR (200 ng) induced a prominent bandshift of the free 
riboprobe (fig. 37). The intensity of this shifted band was not at all afffected by 
the presence of SSAT (fig.37). Therefore, this finding demonstrates that SSAT 
does not affect the binding of HuR to the 3-UTR of sGC α-1 mRNA.   
  112IV Discussion 
Soluble guanylyl cyclase (sGC) is a key signaling component
 of the L-arginine-
NO-cyclic GMP pathway (Bellamy TC, 2002);(Denninger JW, 1999). The 
propagation of NO signaling
 via cyclic GMP formation is influenced at different 
time scales,
  most rapidly by allosteric activation of heterodimeric sGC upon
 
binding of NO to its heme-iron. In addition, NO signaling may
  be affected by 
altered expression of sGC subunits, as has been
 shown in different pathological 
conditions (Kloss S, 2000);(Li D, 1999;Marques M, 2001);(Mulsch A, 
2001);(Takata M, 2001);(Telfer JF, 2001);(Tzao C, 2001) and developmental 
stages (Behrends S, 2001);(Bloch KD, 1997);(Giuili G, 1994);(Ibarra C, 
2001);(White CR, 2000). The molecular mechanisms underlying altered sGC
 
expression in these and other conditions have not yet been revealed.  
 
Elevation of intracellular cGMP can decrease mRNA levels of
 sGC α-1 and β-1 
subunits, iNOS, COX-2, TNF-α, and TGF-β3
  via message destabilization in 
VSMCs, mesangial cells, and cardiac
  fibroblasts (Alexandra K.Kiemer and 
Angelika M.Vollmar, 1998);(Dolores Pérez-Sala, 2001);(Filippov G, 1997);(Kloss 
S, 2003);(Nadia Abdelaziz, 2001);(Sinha B, 1998).
 Stability of sGC α-1 mRNA is 
regulated
 by the ubiquitous mRNA binding protein HuR, which binds to AU-rich
 
elements in the 3'-untranslated region (UTR) and increases mRNA
  half-life; 
cGMP-elevating agents decrease expression and RNA
 binding of HuR, thereby 
destabilizing sGC α-1 mRNA (Kloss S, 2003). The cGMP-induced
  mRNA 
destabilization requires transcription of an unknown factor(s) (Kloss S, 
2003);(Nadia Abdelaziz, 2001);
 this could be an RNA-destabilizing protein or a 
factor involved
 in downregulation of HuR.
  
 
This study was performed in an effort to provide some insight to the 
transcriptional and post-transcriptional regulation of sGC expression in a 
mammal, the rat. The sGC α-1 subunit promoter was analysed for the regulation 
of gene expression and the responsible transcription factors were identified. 
  113Evidence of sGC regulation at the transcriptional level in response to a stimulus 
was observed and the possible mechanism was outlined. An effort was made to 
characterize the molecule affecting the stability of sGC mRNA.  
 
1  Influence of genomic organization on transcriptional regulation of 
sGC subunits within different species 
Comparison of the genomic organization of α-1 and β-1 sGC genes
 between rat, 
Medaka fish, mouse, and human (Azam M, 1998);( Giuili G, 1993);( Sharina IG, 
2000);( Yao Y, 2003) (species where the sGC
  genomic organization was 
resolved) demonstrated several interesting
 features. The mammalian α-1 and β-1 
sGC genes are further from each
 other on the chromosome than the Medaka fish 
genes. In the latter species they
 are separated by only 1 kb (Mikami T, 1999), 
suggesting a concerted regulation of expression of both subunits. Indeed, 
tandem genomic organization relates to a directly coordinated transcription for α-
1 and β-1 subunits in
  Medaka fish (Mikami T, 1999), however, this option
  is 
topologically excluded in mammals. The mouse α-1 and β-1 sGC genes map to 
the third chromosome. However, they are separated from each other by an
 
extended region comprising 2% of the total chromosomal length.
 Probing of the 
Human Genome Database with the mouse and human cDNA sequences 
identified the clone AC021433, which contains
  eight exons of the human α-1 
gene and 14 exons of the human β-1 gene. This fragment is ascribed to human 
chromosome 2. The rat α-1 and β-1 genes map to chromosome 2. 
 
The transcriptional activity
 of promoters for mouse α-1 and β-1, and human β−1 
genes have also been demonstrated to be different (Sharina IG, 2000). 
Independent
 transcription of different sGC subunits existing in mammals
 could be 
beneficial in tissue-specific regulation of expression,
 which was speculated to be 
one mechanism of regulation of sGC
 activity (ref. (Andreopoulos S, 2000) and 
references therein). 
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examined. Recently, evidence to support altered
 expression of mRNA of sGC 
subunits has emerged. In primary rat
  pulmonary artery smooth muscle cells, 
prolonged NO treatment leads
  to decreased NO-stimulated sGC activity and 
mRNA levels (Filippov G, 1997).
 sGC levels rise in unborn rat pulmonary artery, 
beginning at approximately
 20 days of gestation, and mRNA, protein, and activity 
remain elevated
 at least 8 days after birth (Bloch KD, 1997). Decreased rates of 
sGC transcription
 also have been suggested in other models after NO treatment 
and
 administration of cAMP-elevating agents (Behrends S, 1995);(Chhajlani V, 
1991). Furthermore,
 nerve growth factor administration to rat PC-12 cells results
 
in decreased steady-state levels of sGC α−1 and β−1 mRNA (Liu H, 1997). 
Estrogen treatment has been reported to decrease
  α−1 and β−1 sGC mRNA 
levels in rat uterus (Krumenacker JS, 2001). However the precise mechanisms 
underlying these effects on sGC in specific
  tissues are largely unknown. Our 
findings on the activity of putative
  promoter regions demonstrate basal 
transcriptional activity
 for sGC α-1 subunit. These data represent the first studies 
on the transcriptional
 regulation of rat sGC genes and will help to gain insights on 
the genetic basis of regulation
 of this important
 enzyme. 
 
2  Basal activity of sGC α-1 promoter 
The studies performed by Dr. Meik Behrens showed that the sGC subunits in rats 
are also independently regulated. GenomeWalking from the 5’ UTR of the α-1 
subunit resulted in different clones that were subsequently sequenced and 
cloned into the pGL3basic vector (Invitrogen) containing luciferase as reporter 
gene. For the α-1 subunit following clones were obtained Alpha3000 (with -2794 
bp), Alpha1100 (-1092 bp), Alpha350 (-346 bp) and Alpha200 (-200 bp) (see fig. 
1). Transfection of the constructs of both subunits in rat vascular smooth muscle 
cells resulted for the Alpha3000 construct in a 8.4±2.2 fold, the Alpha1100 a 
3.2±fold, Alpha350 a 15.1±1.8 fold and Alpha200 a 28.4±4.7 fold induction 
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~200bp upstream showed highest level of activity. The changes in the activity 
among Alpha200, Alpha350, Alpha1100 would indicate the presence of a 
repressor(s) between –200 and -3000 bp, and an enhancer element(s) located 
200 bp upstream of the transcriptional start site. The 1100 bp deletion caused a 
5-fold decrease in activity, suggesting that putative enhancers were located in 
between –3000 and –1100 bp and –1100 and –350 bp. Since the promoter 
activity was the highest in the Alpha200 construct, it suggested that this fragment 
contains all the crucial elements necessary to support basal transcription of the 
sGCα1 gene. Hence Alpha200 was chosen to validate the results in RLF-6 cells. 
Promoter analysis in cultured rat aortic smooth muscle cells was hampered by 
the low efficiency of transfection wih the promotor-luciferase constructs, which 
would have made it difficult to observe changes in promoter activity in response 
to various stimuli. Since the RLF-6 cells were found to give five-fold higher 
signals as compared to the primary smooth muscle cells, the RLF-6 were used 
for subsequent experiments. Another advantage of these cells as a model to 
investigate transcriptional activity of sGC was that this cell line consistently 
expresses high levels of the α−1/β−1 sGC heterodimer. Transiently transfected 
luciferase reporter constructs harboring 0.2 and 3.0 kb of α-1 sGC upstream 
sequence were analysed for promoter activity (Fig. 3). As expected, Alpha200 
construct resulted in a 6.02+-0.41-fold induction as compared to Alpha3000 
construct. Since the promoter activity was the highest in the 0.2 kb construct, it 
suggested that this fragment contains all the crucial elements necessary to 
support basal transcription of the sGC α-1 gene. 
 
Functional analysis of constructs containing different size
  fragments of the 5'-
flanking region demonstrated a variable
  profile of activity, suggesting the 
presence of several enhancers
 and repressors functioning at a distance from the 
regulatory
 promoter. The Alpha200 construct demonstrated the highest
 activity, 
indicating that the regulatory promoter of the α-1 sGC
 encompasses ~200 bp 
preceding the transcriptional start site. In
  the present report, we focused on 
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 and identification of the transcriptional factors 
responsible
 for the constitutive transcription of a1 sGC in RLF-6 cells. The
 α-1 
sGC gene possesses a TATA-less promoter. Mouse α-1 promoter and human β-
1 promoter for sGC which have been analysed have been both found to be 
TATAless promoters (Sharina IG, 2003);(Vazquez-Padron RI, 2004). Detailed 
sequence
  analysis revealed several putative binding sites in the immediate
 
proximity of the start site, which were subsequently analysed.  
 
3  NFY and Sp1 are responsible for the basal expression of sGC α-1 in 
RLF-6 cells 
Analysis of the 5' UTR of the rat α-1 sGC gene revealed a multiplicity
 of putative 
transcription factor binding sites that seemed to
 be clustered along the promoter 
region. The presence
  of multiple copies of putative binding sites for 
transcriptional
 factors involved in hematopoietic development and differentiation,
 
such as GATA1, LMO2, IK2 (Schmitt C, 2002), (Wadman IA, 1997), and factors 
involved in morphogenesis
 and development, such as Sox5, Prx2 and Nkx-2.5 
(Jamali M, 2001);(Smits P, 2003);(ten Berge D, 2001),
  is noteworthy. The 
relevance of this observation is substantiated
 by evidence that sGC activity is 
important during embryogenesis
 (Bloch KD, 1997);(Harumi T, 2003);(Smigrodzki 
R, 1996);(Yamamoto T, 2003). However, it would require further studies
  to 
address the mechanism of α−1 sGC transcriptional regulation
  during 
development and hematopoiesis. 
  
The
  functional significance of consensus transcriptional factor
  binding sites 
proximal to the transcriptional start site was
 investigated by decoy oligonucleotide 
approach and site deletions in the full length and the 200-bp promoter fragment.
 
The elimination of CCAAT-binding factor (NFY) binding core significantly 
diminished
 whereas deletion of the Sp1 core elevated the transcription rate (fig. 
14). Electrophoretic mobility-shift assay (EMSA) confirmed the interaction
 of NFY, 
and Sp1 factors with the sGC α-1 promoter (figs. 18 and 20). Treatment
 of RLF-6 
  117cells with genistein and mithramycin A, known to inhibit the NFY binding and Sp1 
binding
 to DNA respectively, significantly reduced protein levels of sGC α-1 by 
inhibiting
 transcription (figs. 16, 17 and 21). In summary, our study represents an 
analysis
 of the rat sGC α-1 promoter regulation in RLF-6 cells and identifies NFY 
and Sp1 as critically important factors
 in sGC α-1 expression 
 
Core deletion of the sites caused a markedly visible reduction in the activity of 
both the Alpha200 and the Alpha3000 constructs (fig. 14), emphasising the 
significance of these sites in the promoter activity. Also it became clear that Sp1 
is indeed an activating element for both the long and the short fragments. The 
use of decoy ODN and chemical inhibitors are indirect approaches and could 
lead to diverse changes in the cell so that the results observed in those cases 
can be contributed to that effect. 
 
 As shown in fig. 19 the abundance of the targeted transcription factors were 
reduced in the cells treated with the corresponding decoy ODN. Transfection with 
the transcription factors CABL and MZF decoy ODN had no effect on the 
promoter activity (fig. 11). In contrast, the NFY-specific decoy resulted in a 
significant decrease, indicating that NFY could function as an enhancing element 
in basal sGC α−1 core promotor activity. The Sp1-specific decoy resulted in an 
increase of the promoter activity, which could mean that this factor might be 
involved in a negative regulation of sGC α−1 transcription.  
 
 Treatment of RLF-6 cells withinhibitors of the transcription factors NFY and Sp1 
confirmed the results from the decoy experiment and established NFY as the 
activating and Sp1 as the repressing element in the 200 bp construct. Also it 
clearly demonstrated that the effects of mithramycin A on the Alpha200 and the 
Alpha3000 construct are completely opposite. This finding could mean that Sp1 
acted as a repressor for the site present in the 200 bp region whereas its effect 
was to activate when it was bound to the other sites in the long construct. 
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oligos (figs. 18, 19 and 20). Several transcription factors are able to bind the 
CCAAT consensus sequence; among them are NFY-A, B and C subunits, 
likewise Sp1, 2, 3 and 4 for the Sp1 consensus sequence. To identify the 
transcriptional factors bound to the respective probes, we performed a supershift 
analysis by using antibodies dirtected against these putative transcription factors. 
With the CCAAT probe, a supershift was achieved with an antibody specific for 
NFY-B. The presence of NFY-A antibody did not produce a supershift, however, 
it induced a decrease of band intensity in the formed complexes, suggesting that 
formation of protein/DNA complexes with the probe could depend on the 
availability of this factor. With the Sp1 probe, antibody against Sp1 led to a shift 
of the complex. These results indicated that NFY-B and Sp1 are the major 
components of the protein complexes bound to the CCAAT and the Sp1 probes 
respectively. 
 
The CCAAT box is one of the most common elements in eukaryotic promoters, 
found in the forward or reverse orientation (Mantovani R., 1999). One of the 
various DNA binding proteins that interact with this sequence is NFY. NFY 
consists of three different subunits, NFY-A, NFY-B, and NFY-C, that all are 
necessary to form a NFY-DNA complex (Hooft van Huijsduijnen R, 1990);(Maity 
SN, 1992);(Maity SN, 1990);(Sinha S, 1995);(Vuorio T, 1990).
  Specific amino 
acid segments in each NFY subunit are highly conserved
 during evolution. Only 
NFY (NFY, HAP2/3/4/5) has been shown to absolutely require all 5 nt. The 
frequency of CCAAT boxes appears to be relatively higher in TATA-less 
promoters, particularly in the reverse ATTGG orientation. The sGC α-1 promoter 
has the CCAAT box in the reverse orientation and is a TATA-less promoter. In 
TATA-containing promoters the CCAAT box is preferentially located in the -80/-
100 region (mean position -89) and is not found nearer to the Start site than -50. 
In TATA-less promoters it is usually closer to the +1 signal (at -66 on average). 
The rat sGC α−1 has the CCAAT box at –65. Similarly, the promoter region of 
human sGC β−1, which is also TATA-less, has the CCAAT box at –50 in the 
  119reverse orientation. This box is essential for the basal promoter activity (Sharina 
IG, 2003). 
 
Elevated levels of sGC expression
  and high cGMP content were detected in 
human bladder carcinoma
 in comparison with normal tissue (Ehsan A, 2002). It 
has also been recognized
 that tumors have altered guanylyl cyclase activity and 
that
  tumor bearing animals have elevated cGMP urinary excretion (Murad F, 
1975), (Kimura H, 1975b). Conversely, genistein, has been found to inhibit the 
growth
  of carcinogen-induced cancers in rats and human leukemia cells
 
transplanted into mice (Zhou JR, 1998). Since we found that genistein inhibited 
the expression of sGC α−1 (fig. 15) it is temptive to speculate that the anti-cancer 
activity of genistein may be related to its ability to reduce the level of sGC α−1 
expression and consequently NO-dependent generation of cGMP by sGC. 
 
Sp1 was originally characterized as a transcription factor that recognized GC-rich 
sequences in the early promoter of Simian Virus 40 (Dynan WS, 1983);(Gidoni D, 
1984). Sp1 is considered to be a constitutively expressed transcription factor and 
has been implicated in the regulation of a wide variety of housekeeping genes, 
genes that are expressed in a tissue-specific manner, and genes involved in the 
regulation of growth such as in cell cycle or mammalian development (Hagen G, 
1994). The embryos of Sp1-null mice exhibit severely retarded growth and die 
after day 10 of embryonic development (E10) (Marin M, 1997). Thus, it is likely 
that Sp1 is essential for the differentiation of embryonic stem (ES) cells after day 
10 of gestation. Sp1 is one of the first cellular transcription factors to be 
identified, cloned and characterized for its ability to bind to GC-boxes in 
regulatory promoter elements. It belongs to the Sp family of transcription factors 
that currently includes four proteins designated Sp1, Sp2, Sp3 and Sp4 (Suske 
G., 1999). 
 
Sp1 interacts with many factors, such as the TATA-box-binding protein (TBP), 
which is a major component of the general transcriptional machinery, as well as 
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N, 1996), and hTAFII55 (Chiang CM, 1995). Other proteins, such as transcription 
factors YY1 (Lee JS, 1993),(Seto E, 1993), E2F (Karlseder J, 1996);(Lin SY, 
1996) and co-activators p300/CBP (Billon N, 1999);(Xiao H, 2000) and CRSP 
(cofactor required for Sp1 activation) (Naar AM, 2002);(Ryu S, 1999);(Taatjes DJ, 
2002), have also been reported to associate with Sp1. A specific protein-protein 
interaction between the glutamine-rich region of Sp1 and hTAFII130 is required 
for recruitment of general transcription factors (Dunah AW, 2002).  
 
Sp1 and NFY have also been shown to interact (Roder K, 1999), which can play 
an important role, in regulation of promoters where both transcription factors 
have overlapping binding sites. Examples are  the Sp1 gene promotor itself, the 
major histocompatibility complex class II-associated invariant chain, and sGC 
α−1 gene promoter (Nicolas M, 2003);(Wright KL, 1995). Analysis of the Sp1 
gene promoter showed that both factors compete for the NFY/Sp1 overlapping 
box whereas in the MHC invariant chain promoter the expression was 
upregulated by cooperative interactions of the factors. The sGC α−1 promoter 
has the overlapping NFY/Sp1 region at bases –60 to –65 from transcription start. 
Our experiments performed to analyse this promotor region suggested that NFY 
had an activating and Sp1 had a silencing effect on sGC α−1 gene expression. It 
is possible that the regulation of the sGC α−1 promoter depends on the 
interaction between both factors. This interaction could be either synergistic or 
competitive. Also the interaction between both factors might change in response 
to an external stimulus, leading to an up- or downregulation of sGC α−1 gene 
expression. 
 
  1214  Serum downregulates the sGC α-1 Expression in RLF-6 cells 
When we exposed serum-starved RLF-6 cells or freshly isolated rat aorta to 10 
% fetal calf serum for 24 hours and then analysed the cells and tissue for 
expression of sGC α−1 we observed a marked down-regulation at the mRNA and 
protein level (figs. 22 and 23). In consistency with the above observations, 10% 
FCS also led to a decrease in the activity of the sGC α−1 promoter, as assessed 
by luciferase reporter assay (fig. 24).  
 
Proliferation of vascular smooth muscle cells (VSMCs) is an important 
pathological event in a number of vascular disease processes including 
atherosclerosis, the response to endothelial injury, vascular rejection, 
hypertension or normal aging (Laurent S, 1996);(Pilz RB, 2003). Serum has been 
shown to have a mitogenic effect on the proliferation of smooth muscle cells. By 
studying the growth patterns of VSMC from spontaneously hypertensive rats 
(SHRs) vs. those obtained from their normotensive counterparts, Wistar-Kyoto 
(WKY) rats, it was demonstrated that VSMC from SHRs exhibited a higher 
specific growth rate, abnormal contact inhibition, and accelerated entry into the S 
phase of the cell cycle (Kloss S, 2000). Moreover, they were hyperresponsive to 
many growth factors such as calf serum, epidermal growth factor (EGF), platelet-
derived growth factor (PDGF), transforming growth factor beta 1 (TGF beta 1), 
and insulin. These intrinsic growth anomalies in cells of hypertensive origin 
persist in culture indicating their putative primary role in the pathogenesis of 
hypertension (Ghosh J, 2005);(Mikhail N, 1993). In context of these observations, 
serum has also been found to up-regulate the expression of Thrombospondin-1 
in vascular smooth muscle cells, which has a mitogenic effect on the cells 
(Framson P, 1993). Thrombospondin-1 has also been implicated in the 
development of various pathophysiological conditions associated with the 
proliferation of smooth muscle cells (Schellings MW, 2004).  
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peptides by sGC, is a key regulator of vascular smooth muscle cell contractility, 
growth, and differentiation, and is implicated in opposing the pathophysiology of 
hypertension, cardiac hypertrophy, atherosclerosis, and vascular 
injury/restenosis (Pilz RB, 2003). The decrease in sGC α-1 expression by FCS 
reiterates its proliferative effect and provides a possible mechanism of this down-
regulation. Thus FCS, down-regulates sGC α-1, which in turn lowers the cGMP 
content in the cellular environment which leads to the proliferation of smooth 
muscle cells. Indeed, expression of both sGC subunits (α-1 and β-1) was found 
decreased in aortic tissue of aged SHR as compared to aged WKY rats (Klöss, 
Bouloumie, Mülsch 2000).  
 
5  Downregulation of sGC α-1 by serum is mediated by NFY and Sp1 
In an effort to characterise the molecular mechanism of the serum-induced down-
regulation of sGC, we studied the effect of serum on the activity of the 
transcription factors Sp1 and NFY, the main transcription factors identified in the 
constitutive expression of sGC α-1. Cell lysates from both control and FCS 
treated RLF-6 cells were used in the EMSA with Sp1 and NFY cognate DNA 
oligos. These studies revealed that in the presence of FCS, NFY binding 
decreased, whereas Sp1 binding increased (fig. 25), in comparison to serum-
starved cells. This observation corroborated our previous findings that these 
factors regulate the expression of sGC α-1 in an opposite manner. 
 
NFY and Sp1 are ubiquitous transcription factors involved in the constitutive and 
inducible expression of a lot of mammalian genes (Mantovani R., 1999);(Suske 
G., 1999). Sp1 has been found in the promoters of mouse sGC α-1 and human 
NPR-B gene (Garg R, 2002);(Rahmutula D, 2004). NF-Y plays an important role 
in the human β-1 sGC promoter regulation (Sharina IG, 2003). NFY- and Sp1- 
cognate sequences have been found in the mouse and human NPR-A promoter 
as well as in the rat NPR-A promoter where NFY and Sp1 act synergistically to 
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association between NFY and Sp1 has been demonstrated both in vitro and in 
vivo.  
In case of rat sGC α−1 promoter where the binding sites for NFY and Sp1 
overlap, we propose that under normal conditions, NFY is the dominat factor 
regulating promotor activity. However, the presence of FCS causes a shift in 
transcription factor activity, enabling Sp1 to bind to the same site and exert its 
suppressing effect. This was evident from the tests performed with the Alpha200 
construct in the presence of Sp1 decoy and mithramycin A. The pathway leading 
to this shift caused by FCS remains to be elucidated. Also the involvement of 
other transcription factors besides NFY and Sp1 remains unknown. 
 
6  Activation of AP-1 is responsible for the HuR mediated 
downregulation of sGC 
The 3'-untranslated regions (UTR) of the sGC α-1 and β-1 mRNA bear AU-rich 
elements (ARE), which are targeted by
  trans-acting factors for regulation of 
mRNA stability. One of
 these factors is the elav-like ubiquitous 34-kDa protein 
HuR.
 Recently,
 HuR and other ARE-binding proteins were also found to regulate
 
translation of target mRNAs, by recruitment to mammalian stress
  granules 
formed in response to metabolic stress (Kedersha N, 2002). HuR is down 
regulated in rat vascular smooth
  muscle cells (Kloss S, 2003) and mesangial 
cells (Akool el-S, 2003) by cGMP-eliciting agonists.  
Forskolin, a cAMP-eliciting direct activator
  of adenylyl cyclase, and PKA-
activating cAMP analogs were found to decrease
 the expression of both HuR and 
sGC in isolated rat aorta, at
 the protein and mRNA levels in a time-dependent 
fashion (Kloss S, 2004). In the absence of cAMP-eliciting conditions, a markedly 
slower decrease in HuR and sGC expression in rat
 aortic tissue was observed. 
The interaction of endogenous HuR with
  ARE-containing oligoribonucleotides 
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extracts from
 forskolin-exposed aorta, and this effect was blocked by Rp-cAMPS,
 
an PKA-inhibitory cAMP analog. A decreased
 expression of HuR at the protein 
and mRNA levels was the most
  likely explanation for the reduced HuR sGC 
mRNA interaction. As a consequence of decreased HuR expression and mRNA
 
binding activity, the stability of sGC α-1 and β-1 mRNA in in vitro
 degradation 
assays was considerably reduced by native protein
  extracted from forskolin-
exposed aortic tissue, compared with
 protein from control aorta. These findings 
clearly
 show that HuR expression and activity is decreased by the cAMP/PKA
 
signaling pathway (Kloss S, 2004). This mechanism probably accounts for 
decreased
  expression of sGC subunits, because HuR-dependent protection
 of 
sGC mRNA is lost. We cannot exclude the
 possibility that additional mechanisms 
could contribute to the
  cAMP-elicited decrease of sGC mRNA stability [e.g., 
induction
 of mRNA-destabilizing factors such as AUF 1, but HuR seems to play a 
pre-eminent role in sGC mRNA stability
 regulation.
 
It was also observed that forskolin induced a very rapid increase in Fos and
 
activated p-Fos that was accompanied by a transient
  activation of AP-1, the 
heterodimeric transcription factor constituted
  by Fos and Jun. A causal 
relationship between AP-1 activation
 and HuR depression was established by an 
AP-1 decoy approach. Competition of an exogenously provided
 AP-1 cognate 
dsDNA oligonucleotide with endogenous AP-1 sites
  inhibited forskolin-induced 
depression of HuR. However,
 the complete sequence of signaling events leading 
to HuR depression
 by AP-1 activation remains to be elucidated. The mouse HuR 
promotor
  bears several AP1 and a conserved CREB site(s) (King PH, 2000), 
which could also mediate a direct silencing effect of
  cAMP on HuR promotor 
activity. It is noteworthy that quite similar
  signaling seems to account for 
NO/cGMP-induced down-regulation
 of HuR; it had been observed that the sGC 
activators
 YC-1 and sodium nitroprusside rapidly and transiently increased
 Fos 
and activated AP-1 in RASMC (S. Kloess, A. Muelsch, unpublished
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gene expression. 
 
7  HuR interacts with the protein SSAT 
In an effort to understand the intracellular interactions that regulate the activity of 
HuR in stabilizing ARE containing mRNA, several protein ligands to HuR have 
been identified and characterized (Brennan CM, 2000). They are SETa:b 
(Matsumoto K, 1993);(von Lindern M, 1992), pp32 (Malek SN, 1990) and acidic 
protein rich in leucine (APRIL) (Mencinger M, 1998). Deletion experiments 
suggested that the acidic tail of at least pp32 (and possibly these other HuR 
ligands) is required for their interaction with a region spanning the hinge region 
and third RRM of HuR (Brennan CM, 2000). SSAT (Spermidine/spermine N1-
acetyltransferase) here has been found to interact with HuR through its hinge 
region. The hinge region of HuR also harbours its HNS (HuR Nucleocytoplasmic 
Shuttle) sequence (Fan XC, 1998b). It is yet to be investigated whether HuR 
ligands, including SSAT, increase the affinity of HuR for its target mRNAs or do 
they regulate HuR export, thereby modulating its ability to stabilize ARE-
containing mRNAs. 
 
We found here that the hinge region of HuR interacts with the catabolic enzyme 
SSAT. The oxidative catabolism of the higher order polyamines, spermidine
 and 
spermine, is accomplished by the concerted action of two
  different enzymes, 
SSAT and polyamine oxidase (PAO) (Casero RA Jr, 1993). Cytosolic
 SSAT N
1 
acetylates both spermidine and spermine, which then
  serve as substrates for 
peroxisomal PAO. Because
  PAO strongly prefers acetylated polyamines to 
unmodified polyamines
 as its substrates, SSAT is generally considered the rate-
controlling
  enzyme in the back conversion of the higher order polyamines,
 
spermidine and spermine, to the lower order polyamine, putrescine. Thus far, 
spermine and spermidine are
 the only physiological substrates that have been 
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 for SSAT (Chen C, 2004). Therefore, it is tempting to speculate that 
SSAT affects HuR functions by local effects on polyamines. 
A direct effect of these proteins on each other’s biological activity was not visible 
as tested through the SSAT activity assay and HuR gel shift. HuR failed to affect 
the enzymatic activity of SSAT and SSAT-GST did not have any effect on the gel 
shift performed by HuR on the 3’ UTR of sGC α-1. However more direct/indirect 
assays need to be performed to unearth the functional rationale of this 
interaction. Indeed, previous studies have implicated polyamines in the regulation
 
of cell cycle; Cyclin A expression is lowered in cells treated with polyamine 
biosynthesis inhibitors (Oredsson SM., 2003). HuR plays a critical role in cell 
proliferation, at least in part by mediating cell cycle-dependent stabilization of 
mRNAs encoding cyclins A and B1 (Wang W, 2000). Depletion of polyamines by 
treatment with
 DFMO, a drug that blocks the enzyme ornithine decarboxylase
 
responsible for conversion of ornithine to putrescine, has been
 shown to alter the 
expression of cyclin A during cell cycle (Oredsson SM., 2003).
 NO inhibits VSMC 
proliferation by specifically changing the expression and activity of cell cycle 
regulatory proteins. Adenoviral overexpression of endothelial NOS represents a 
cytostatic strategy for gene therapy of vascular disease (Tanner FC, 2000). Thus, 
it is conceivable that SSAT-mediated modulation of local
  polyamine 
concentrations enhances/reduces HuR activity and sGC expression to affect
 cell 
proliferation. Since SSAT interacts with HuR through its hinge region, which has 
the nucleocytoplasmic shuttling sequence, it is possible that it affects the mRNA-
transporting function of HuR. However, an equally plausible hypothesis is
 that 
SSAT is involved in acetylating other unknown substrates
  whose acetylation 
affects their role in the cell cycle. However, it still needs to be investigated how 
the HuR-SSAT interaction affects sGC expression and mRNA stability as well as 
the effect of these in cell proliferation. 
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Soluble guanylyl cyclase (sGC) is a cytosolic enzyme producing the intracellular 
messenger cyclic guanosine monophosphate (cGMP) on activation with nitric 
oxide (NO) which leads to the activation of GMP dependent protein kinases and 
to vasodilation. NO signaling may
  be affected by altered expression of sGC 
subunits, as has been
  shown in different pathological and physiological 
conditions and developmental stages. The molecular mechanisms underlying 
altered sGC
  expression in these and other conditions have not yet been 
revealed.  
  
Gene expression can also be regulated at the level of mRNA through alterations 
in translational efficiency and in mRNA stability. HuR (Human R) is a ubiquitously 
expressed member of the embryonic lethal abnormal vision (ELAV) family of 
RNA-binding proteins. Among other RNAs, there has been recent evidence that 
the expression of sGC is subject to post-transcriptional
 regulation by HuR. It has 
been shown that chronic hypertension induces changes
 in HuR expression and 
activity, which account for decreased
 sGC expression and activity in the aorta of 
hypertensive rats. 
 
This thesis should study was performed in an effort to provide some insight to the 
transcriptional and post-transcriptional regulation of sGC expression in a 
mammal, the rat.  
 
We investigated rat sGC α-1 transcriptional regulation in rat lung fibroblast 
(RLF-6) cells. The 3000bp 5' upstream region of the α-1 sGC gene was isolated 
and analyzed for promoter activity by using luciferase reporter constructs- 
Alpha3000 (with -2794 bp), Alpha1100 (-1092 bp), Alpha350 (-346 bp) and 
Alpha200 (-200 bp). The promoter activity was the highest in the 200bp construct 
(about 6-fold higher than Alpha3000) suggesting that this fragment contains all 
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gene.  
 
Analysis of the 200 bp of the 5’ UTR of the α−1 gene was performed using the 
MATINSPECTOR V2.2 software for putative transcription factors. The constructs 
containing the deleted sites for NFY and Sp1 showed a significant decrease in 
constitutive promoter activity by almost 80% and 60% respectively, implying that 
these transcription factors are crucial elements in the basal expression of the of 
sGC  α−1 subunit. Treatment of RLF-6 cells with genistein 50 µM and 
mithramycinA 100 nM, known to inhibit the NFY and Sp1 binding to DNA 
respectively, reflected the same effects. Furthermore the cGMP content of the 
cells was significantly reduced by both inhibitors, almost completely by genistein, 
and by about 40 % by mithramycinA.   
 
Electrophoretic mobility-shift assay (EMSA) clearly showed the formation of 
multiple complexes with the biotinylated ODN (decoy oligodeoxynucleotide) 
probes for NFY and Sp1 when incubated with RLF-6 nuclear extract. A 
“supershift” observed in the presence of antibodies to the individual transcription 
factors confirmed that these factors were present in the shifted band, indeed. 
 
NFY and Sp1 are instrumental in several physiological and pathophysiological 
effects mediated by several growth factors in smooth muscle cells. Thus the 
regulation of the promoter, in response to serum, was also analysed. 10% foetal 
calf serum led to decreased α-1 sGC level as shown by western blots performed 
with rat aorta. Decreased sGC α-1 mRNA expression was observed in RLF-6 
cells and cultured rat aortic smooth muscle cells incubated with FCS for 24 
hours. This decrease was reflected in the promoter activity in RLF-6 cells using 
both Alpha3000 and Alpha200 constructs confirming that the regulation took 
place at promoter level. 
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diminished binding to NFY, but to an enhanced binding to Sp1 site. We 
concluded that the factors Sp1 and NFY (the sites overlapping) compete for 
binding, and in the presence of FCS, it is Sp1 that binds stronger, and hence 
results in diminishing promoter activity.   
 
In order to delineate the post-transcriptional regulation of sGC α-1 subunit, 
studies were performed to demonstrate the regulation of expression of the mRNA 
stabilizing protein HuR. It has been observed that exposure of isolated rat aortic 
segments to the activator of
 adenylyl cyclase, forskolin, strongly reduced sGC 
α−1/β−1 and
  HuR protein and mRNA expression in a time-dependent and 
actinomycin
 D-sensitive fashion. Transcription factor decoy
 approach proved that 
the cAMP-induced
 down-regulation of HuR is mediated by the activation of AP-1. 
 
It has been established that HuR stabilises the sGC α−1 and β-1 mRNA. 
However the pathway underlying this regulation remains unknown. In order to 
identify the mechanism of this regulation, we looked for HuR interacting proteins 
employing the yeast two hybrid assay. The enzyme of the polyamine catabolic 
pathway spermidine/spermine N1-acetyltransferase (SSAT) was found to interact 
with the hinge region of HuR. This interaction was confirmed by performing 
immunoprecipitation and GST-pulldown experiments. A direct effect of these 
proteins on each other’s biological activity was not visible as tested through the 
SSAT activity assay and HuR gel shift. It might be possible that SSAT-mediated 
modulation of local
 polyamine concentrations enhances/reduces HuR activity and 
sGC expression to affect
 cell proliferation. 
 
In summary, this study represents an analysis of the rat sGC α-1 promoter 
regulation in rat fibroblast cells and identifies NFY and Sp1 as important factors 
in sGC α-1 expression. It also gives first evidence of sGC regulation at the 
transcriptional level in response to an external stimulus, and proposes the 
possible mechanism. It also identifies SSAT as a HuR interacting protein. These 
  130might have implications in the various pathophysiological conditions where sGC 
plays an important role. 
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  156VII Appendix 
1 Abbreviations 
 
AC       Adenylyl  cyclase 
A c t .   D        A c t i n o m y c i n   D  
ADP       Adenosine  diphosphate 
Amp       Ampicillin   
A N F        A t r i a l   N a t r i u r e t i c   F a c t o r  
AP-1       Activator  protein  1 
ATP       Adenosine  triphosphate 
bp       Base  pair   
BSA       Bovine  serum  albumin   
cAMP       cyclic  Adenosine  monophosphate 
cGMP       cyclic  Guanosine  monophosphate 
CRE       cAMP  responsive  element 
kDa       kilo  Dalton 
dATP       Deoxy-Adenosine  triphosphate 
dCTP       Desoxy-Cytidine  triphosphate 
DEPC       Diethylpyrocarbonate 
dGTP       Desoxy-Guanosine  triphosphate 
DNA       Deoxyribo-nucleic  acid 
dNTP       Deoxy-nucleotide  triphosphate 
DTT       Dithiothreitol 
dTTP       Deoxy-Thymidine  triphosphate 
EDRF       “endothelium derived relaxing factor“ 
EDTA       Ethylene  diamine  tetraacetate 
eNOS       endothelial  NO-Synthase 
GTP       Guanosine-5‘-triphosphate 
h       hour   
HuR                              Human Antigen-R 
  157iNOS       inducible  NO-Synthase 
IPTG       Isopropylthiogalactoside 
k b        K i l o b a s e  
kDa       Kilodalton 
L-NAG     N-Nitro-L-Arginine 
min       Minute   
mg       Milligramm 
µM       Micromole  per  Liter 
µ l        M i c r o l i t e r  
ml       Milliliter 
mM       Millimol  per  Liter 
mRNA       messenger  ribonucleic  acid 
NADH       Nicotinamide adenine dinucleotide 
NADPH Nicotinamide  adenine dinucleotide 
phosphate 
nmol       Nanomol 
NS2028       4H-8-bromo-1,2,4-oxadiazolo(3,4- 
d)benz(b)(1,4)oxazin-1-on 
NTG       Nitroglycerine 
OD       Optical  density 
PAGE       Polyacrylamide  gel  electrophoresis 
PBS       Phosphate-buffered-saline 
PCR       Polymerase  chain  reaction   
PEG       Polyethylene  glycol 
pGC       Particulate  guanylyl  cyclase 
PMSF       Phenylmethylsulfonylfluoride 
RNA       Ribonucleic  acid 
RP-8-Bromo-PET-cGMPS ß-Phenyl-1,N
2-ethene-bromoguanosine 
3’-5’cyclic monophosphorothioate 
rRNA       ribosomal  Ribonucleic  acid 
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 reaction 
sec       Seconds 
SDS       Sodiumdodecylsulfate 
SHR       “spontaneously  hypertensive  rats“ 
SMC       Smooth  muscle  cells 
SNP       Sodiumnitroprusside 
SSAT                                                      Spermidine/spermine N1-acetyl-
transferase 
TBE       Tris-Borate-EDTA 
TEMED      Tetramethylethylendiamine 
Tris       Tris-(Hydroxymethyl)-aminomethane 
tRNA       transfer  Ribonucleic  acid 
U       Unit  (s) 
V        V o l t s  
V o l        V o l u m e s  
W K Y        W i s t a r - K y o t o - R a t t e n  
YC-1 3-(5’-hydroxymethyl-2’-furyl)-1-benzyl 
indazol 
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Die lösliche Guanylatzyklase (soluble guanylyl cyclase, sGC) ist ein 
Schlüsselenzym der NO/cGMP Signaltransduktion im kardiovaskulären System. 
Nach Aktivierung der sGC durch Stickstoffmonoxid (NO) kommt es in glatten 
Muskelzellen zur Produktion von zyklischem 3’,5’-Guanosinmonophosphat 
(cGMP), das als intrazelluläres Signaltransduktionsmolekül die Aktivierung von 
cGMP-abhängigen Proteinkinasen vermittelt und zur Vasodilatation führt.  
 
Die NO/cGMP-Signaltransduktion kann auch auf der Ebene der Gen-Expression 
beeinflusst werden. So konnte in verschiedenen physiologischen bzw. 
pathophysiologischen Modellen gezeigt werden, dass die unterschiedliche 
Expression von sGC-Untereinheiten die NO/cGMP-Signaltransduktion 
beeinflusst.  
 
Die molekularen Mechanismen, die auf der unterschiedlichen Expression der 
sGC-Untereinheiten basieren, wurden bisher noch nicht ausreichend aufgeklärt. 
 
Die Gen-Expression kann auf mRNA-Ebene durch Veränderung der Translation 
und der mRNA- (messenger ribonucleic acid, Boten-Ribonnukleinsäure) Stabilität 
reguliert werden. HuR (Human R) ist ist ein ubiquitär vorkommendes Mitglied der 
embryonic lethal abnormal vision (ELAV-) Familie der RNA-bindenden Proteine. 
Neben der Regulierung anderer Gene gibt es Hinweise darauf, dass auch die 
Expression der sGC einer post-translationalen Regulation durch HuR unterliegt. 
So wurde gezeigt, dass chronischer Bluthochdruck Veränderungen in der HuR-
Expression und -Aktivität verursacht, was zu einer verminderten sGC-Expression 
und -Aktivität in der Aorta von hypertensiven Ratten führt.  
 
 
  160 
 
Diese Arbeit soll einen Einblick in die transkriptionale und post-transkriptionale 
Regulation der sGC-Expression im Rattenmodell liefern. 
 
Im Rahmen dieser Arbeit wurde die translationale Regulation der α-1 sGC-
Untereinheit der Ratte in Rattenlungen-Fibroblastenzellen (rat lung fibroblast 
cells, RLA-6) untersucht.  
Es wurden die 3000 bp der 5´  upstream Region des Gens der α-1 sGC-
Untereinheit isoliert und mit Hilfe von Luziferase-Reporter-Konstrukten - 
Alpha3000 (mit -2794 bp), Alpha1100 (-1092 bp), Alpha350 (-346 bp) und 
Alpha200 (-200 bp) - auf Promotor-Aktivität untersucht. Dabei war die Promotor-
Aktivität des 200 bp Konstrukts am höchsten (ca. 6-fach im Vergleich zu 
Alpha3000). Dies deutete daraufhin, dass dieses Fragment entscheidende 
Elemente enthält, die für die basale Transkription des α-1 sGC Gens nötig sind. 
 
Um nach vermeintlichen Transkriptionsfaktoren zu suchen, wurde die Analyse 
der 200 bp am 5´ UTR des α-1 Gens mit der MATINSPECTOR V2.2 Software 
durchgeführt. Die Konstrukte mit den entfernten Stellen für NFY und Sp1 zeigten 
eine signifikante Verminderung in der konstitutiven Promotor-Aktivität zu fast 80 
und 60%. Dies deutete daraufhin, dass diese Transkriptionsfaktoren 
entscheidend sind für die basale Expression der α-1 sGC-Untereinheit. Die 
Behandlung der RLF-6 Zellen mit Genistein (50 µM) und Mithramycin A 
(100 nM), die die Anbindung von NFY und Sp1 an die DNA inhibieren, führte 
ebenfalls zu einer Reduktion der Promotor-Aktivität. Außerdem war der Gehalt 
von cGMP in den Zellen durch die beiden Inhibitoren signifikant reduziert - mit 
Genistein wurde eine fast komplette Inhibition erreicht und mit Mithramycin A 
eine Reduktion um ca. 40%.  
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Der EMSA (electrophoretic mobility-shift assay) zeigte deutlich die Bildung von 
multiplen Komplexen mit biotinylierten ODN (decoy oligodeoxynucleotide) 
Proben für NFY und Sp1, wenn diese mit RLF-6 Zellkern-Extrakt inkubiert 
wurden. In einem „supershift“ konnten die einzelnen Transkriptionsfaktoren mit 
Antikörpern nachgewiesen werden. 
 
NFY und Sp1 sind an zahlreichen physiologischen und pathophysiologischen 
Prozessen in glatten Muskelzellen beteiligt, die durch Wachstumsfaktoren 
gesteuert werden. Aus diesem Grund wurde die Regulation des Promotors in 
Gegenwart von Serum analysiert.  
 
Mit Western-Blot Analysen konnte gezeigt werden, dass 10  % fötales Kälber-
Serum (foetal calf serum, FCS) zu einer verminderten Expression von α-1 sGC in 
Rattenaortenringen führte. Eine verminderte sGC α-1 mRNA-Expression wurde 
in RLF-6 Zellen und in kultivierten glatten Muskelzellen der Rattenaorta, die mit 
FCS über 24 Stunden inkubiert wurden, demonstriert. Diese Verminderung ging 
einher mit einer verminderten Promotor-Aktivität der Konstrukte Alpha3000 und 
Alpha200 in RLF-6 Zellen, was eine Regulation auf Promotor-Ebene aufzeigte.  
 
EMSA Studien mit Zellkern-Extrakt aus FCS-vorbehandelten RLF-6 Zellen 
zeigten eine verminderte NFY-, aber eine gesteigerte Sp1-Bindung. Daraus 
wurde gefolgert, dass die Faktoren Sp1 und NFY um eine Bindungsstelle am 
Promotor konkurrieren und dass die Gegenwart von FCS zu einer verstärkten 
Sp1-Bindung und damit zu einer verminderten Promotor-Aktivität führt. 
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Um die post-transkriptionale Regulation der α-1 sGC-Untereinheit zu 
demonstrieren, wurden Versuche zur Regulation der Expression des mRNA-
stablisierenden Proteins HuR durchgeführt. Es konnte gezeigt werden, dass die 
Inkubation von isolierten Rattengefäßringen mit Forskolin, einem Aktivator der 
Adenylatzyklase, die sGC α-1/β-1 und die HuR Protein- und mRNA-Expression 
zeitabhängig und Actinomycin  D-sensitiv reduziert. Der Transkriptionsfaktor-
Abbau bewies, dass die cAMP-induzierte Runterregulation von HuR durch die 
Aktivierung von AP-1 vermittelt wird. 
 
Es konnte festgestellt werden, dass HuR die α-1 und β-1 mRNA der sGC 
stabilisiert. Aber die Regulation dieser Signalwege war bisher unbekannt. Um 
den Mechanismus der Regulation zu identifizieren, haben wir nach HuR-
interagierenden Proteinen durch Anwendung des Yeast-two-hybrid assays 
gesucht. Die Enzyme des Polyamin-katabolischen Signalwegs Spermidin/ 
Spermin N1-Acetyltransferase (SSAT) wurden als eine hinge Region von HuR 
entdeckt. Diese Interaktion wurde bestätigt durch Immunopräzipitation und GST-
pulldown Experimente. Einen direkten gegenseitigen Effekt auf die Aktivität 
dieser Proteine war nicht sichtbar, was durch SSAT activity assays und HuR gel 
shifts getested wurde. Es könnte möglich sein, dass die SSAT-vermittelte 
Modulation der lokalen Polyamin-Konzentration die HuR-Aktivität und die sGC-
Expression fördert bzw. vermindert bei der Zellproliferation. 
 
Diese Arbeit zeigt eine Analyse der Promotor-Regulation der α-1 sGC-
Untereinheit der Ratte in Fibroblastenzellen der Ratte und identifiziert NFY und 
Sp1 als wichtige Faktoren in der α-1 sGC-Expression.  
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Die sGC-Regulation auf transkriptionaler Ebene unter Beteiligung der 
Transkriptionsfaktoren NFY und Sp1, ausgelöst durch Serum als externen 
Stimulus, weist auf einen möglichen Mechanismus hin. Außerdem wurde SSAT 
als HuR-Interaktionsprotein identifiziert. Die in dieser Arbeit dargestellte 
Regulation der sGC-Expression könnte Einfluss haben auf verschiedene 
pathophysiologische Zustände.  
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